Decoding function through comparative genomics: from animal evolution to human disease by Maxwell, Evan Kyle
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Decoding function through
comparative genomics: from
animal evolution to human disease
https://hdl.handle.net/2144/15433
Boston University
BOSTON UNIVERSITY 
 
GRADUATE SCHOOL OF ARTS AND SCIENCES 
 
AND 
 
COLLEGE OF ENGINEERING 
 
 
 
 
Dissertation 
 
 
 
 
DECODING FUNCTION THROUGH COMPARATIVE GENOMICS: 
 
FROM ANIMAL EVOLUTION TO HUMAN DISEASE 
 
 
 
 
by 
 
 
 
 
EVAN KYLE MAXWELL 
 
B.S., Virginia Polytechnic Institute and State University, 2008 
M.S., Virginia Polytechnic Institute and State University, 2010 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2015  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 
 EVAN KYLE MAXWELL 
 All rights reserved  
Approved by 
 
 
 
 
 
First Reader _________________________________________________________ 
 Avrum Spira, M.D., M.Sc. 
 Professor of Medicine, Pathology & Laboratory Medicine, and  
 Bioinformatics 
 
 
Second Reader _________________________________________________________ 
 Andreas D. Baxevanis, Ph.D. 
 Adjunct Professor of Bioinformatics, Boston University 
 Senior Scientist, Computational and Statistical Genomics Branch, 
 National Human Genome Research Institute and 
 Assistant Director for Computational Biology, 
 National Institutes of Health 
 
!! iv 
ACKNOWLEDGMENTS 
I am grateful to the many people who have contributed to the success of the work 
presented in this dissertation and who have supported me throughout my academic 
endeavors. I would like to thank Andy Baxevanis for his devotion to my mentorship, and 
always providing guidance, encouragement, inspiration, and academic freedom. It has 
been an absolute pleasure working in the Baxevanis lab, and I appreciate all of the efforts 
dedicated to enriching my graduate experience. 
I would also like to acknowledge the many other mentors who have enabled my 
success in research, including my committee members at Boston University – Drs. Avi 
Spira, John Finnerty, Rick Myers, and Daniel Segre – who have provided me with 
invaluable research guidance and inspiring data to work with; Drs. Joseph Zaia, George 
Church, and Ivan Ovcharenko who all took the time and effort to provide me with 
thought-inspiring projects that contributed to the progress of my graduate training; Dr. 
Timothy Myers, who first gave me the opportunity to join the NIH community and 
helped inspire me to devote my research to bioinformatics; and, finally, Dr. Naren 
Ramakrishnan, who first took me on as an undergraduate research assistant at Virginia 
Tech and taught me to think like a researcher, and later mentored me through my 
Master’s degree. 
 To the past and present members of the Baxevanis lab, I want to thank Drs. Joe 
Ryan, Christy Schnitzler, and Steve Bond for providing me with inspiration, guidance, 
and assistance on the work that contributed to my dissertation. I also owe my thanks to 
my colleagues at NHGRI – Anh-Dao Nguyen, Brandon Perry, Dave Kanney, Derek 
!! v 
Gildea, Gretchen Gibney, Niraj Trivedi, Suiyuan Zhang, Travis Moreland, Tyra 
Wolfsberg, and Vivek Yadav – for creating an enjoyable work environment and offering 
me their various areas of expertise to aide me in my research. I want to acknowledge the 
folks in the NIH Office of Intramural Training and Education and in NHGRI’s Intramural 
Training Office for making the NIH a great place to be a graduate student. I’d also like to 
thank Dr. David Landsman for the work he has done to build and maintain the 
NIH/Boston University Graduate Partnership Program, and for the substantial advice he 
has provided throughout my training. Furthermore, I want to acknowledge and thank the 
respective entities at both NIH and Boston University for providing me the funding to 
pursue my Ph.D., without which my achievements would not have been possible. 
 Finally, I would like to thank my loving wife and family for supporting me 
through my many years of studentship. I would not be where I am today without the 
immeasurable support that they have provided for me along my journey. 
  
!! vi 
DECODING FUNCTION THROUGH COMPARATIVE GENOMICS: 
FROM ANIMAL EVOLUTION TO HUMAN DISEASE 
(Order No.          ) 
EVAN K. MAXWELL 
Boston University, Graduate School of Arts and Sciences, 
and 
College of Engineering, 2015 
Major Professor: Andreas D. Baxevanis, Ph.D. 
 Adjunct Professor of Bioinformatics, Boston University 
 Senior Scientist, Computational and Statistical Genomics Branch, 
 National Human Genome Research Institute and 
 Assistant Director for Computational Biology, 
 National Institutes of Health 
 
ABSTRACT 
 Deciphering the functionality encoded in the genome constitutes an essential first 
step to understanding the context through which mutations can cause human disease. In 
this dissertation, I present multiple studies based on the use or development of 
comparative genomics techniques to elucidate function (or lack of function) from the 
genomes of humans and other animal species. Collectively, these studies focus on two 
biological entities encoded in the human genome: genes related to human disease 
susceptibility and those that encode microRNAs – small RNAs that have important gene-
regulatory roles in normal biological function and in human disease. Extending this work, 
I investigated the evolution of these biological entities within animals to shed light on 
how their underlying functions arose and how they can be modeled in non-human 
species. Additionally, I present a new tool that uses large-scale clinical genomic data to 
!! vii 
identify human mutations that may affect microRNA regulatory functions, thereby 
providing a method by which state-of-the-art genomic technologies can be fully utilized 
in the search for new disease mechanisms and potential drug targets. 
 The scientific contributions made in this dissertation utilize current data sets 
generated using high-throughput sequencing technologies. For example, recent whole-
genome sequencing studies of the most distant animal lineages have effectively 
restructured the animal tree of life as we understand it. The first two chapters utilize data 
from this new high-confidence animal phylogeny – in addition to data generated in the 
course of my work – to demonstrate that (1) certain classes of human disease have 
uncommonly large proportions of genes that evolved with the earliest animals and/or 
vertebrates, and (2) that canonical microRNA functionality – absent in at least two of the 
early branching animal lineages – likely evolved after the first animals. In the third 
chapter, I expand upon recent research in predicting microRNA target sites, describing a 
novel tool for predicting clinically significant microRNA target site variants and 
demonstrating its applicability to the analysis of clinical genomic data. Thus, the studies 
detailed in this dissertation represent significant advances in our understanding of the 
functions of disease genes and microRNAs from both an evolutionary and a clinical 
perspective. 
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INTRODUCTION 
Comparative Genomics 
The publication of the first draft of the human genome in 2001 was instrumental 
to the advancement of biomedical science. It marked the culmination of decades of 
research and development into technologies for cataloging the billions of nucleotides of 
DNA that form the template of human life. The sequencing of the human genome came 
with the expectation of revolutionizing medicine by providing an unprecedented level of 
detail into the underlying biology of a patient. Despite the significance of having the first 
draft of the human genome in-hand, it quickly became clear that obtaining the sequence 
alone was merely the first step to transforming a genome into an actionable medical 
entity. Specifically, determining the complex functions encoded in the genome is not a 
trivial process. Furthermore, the draft human genome was, by definition, a draft; it 
contained errors, pieces were missing, and was a static entity – a single haploid sequence 
representing a single individual opposed to a diploid model that would convey the 
population-wide genomic heterogeneity inherent in humans. In many ways, the 
sequencing of the human genome was a catalyst to the birth and growth of many fields of 
science that aim to tackle open questions that stemmed from the human genome project. 
One such field is comparative genomics. 
Given the complexity encoded in the human genome and the genomes of other 
species, function cannot simply be ascertained by studying a single genome sequence 
independently. The field of comparative genomics is grounded on the idea that 
understanding the differences and similarities that occur between different genomes can 
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inform how parts of the genome function. This is possible due to the process of evolution 
and natural selection; as mutations alter genomes over generations and speciation events, 
selection allows functional units within the genome to become conserved relative to non-
functional or unfavorably functional units. Thus, comparative genomics leverages our 
knowledge of how natural selection works at the genomic level to understand how certain 
parts of the genome function, but also to understand how they evolved. Comparative 
genomics encompasses a broad range of technologies and applications, with comparisons 
defined at levels ranging from a single, diploid genome, entire populations of genomes, to 
the genomes of many species. 
This dissertation presents multiple studies utilizing comparative genomic 
approaches, with emphases on topics related to gene regulatory functions by microRNAs, 
the genetics of human disease, and the evolution of the associated biological mechanisms. 
Chapter 1 presents a study on the evolution of human disease genes, demonstrating that 
different classes of human disease genes have heterogeneous evolutionary origins. 
Effectively, these insights can improve our ability to select model organisms that 
optimize the balance between phenotypic similarity to humans and experimental 
efficiency for human disease gene research. Chapter 2 focuses on the evolution of 
microRNA regulatory functions in animals, utilizing next generation sequencing (NGS) 
data from Mnemiopsis leidyi - a species from the earliest-branching animal phylum, 
Ctenophora - to show that microRNAs most likely evolved after the divergence of the 
animal kingdom from other eukaryotic species. This helps date the emergence of the 
microRNA regulatory pathway (and its components), expanding our knowledge of its 
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conservation and function in our most distant animal relatives. Chapter 3 presents a new 
computational methodology for analyzing clinical genomic data for the purpose of 
identifying genetic mutations that alter microRNA regulatory functions. This tool 
provides a novel approach for performing genome-scale identification and interpretation 
of clinically relevant genomic variants that may affect microRNA functions in the context 
of human disease. Together, the studies presented in this dissertation examine diverse 
aspects of genome functions through comparative and computational genomics, with the 
shared goal of improving the understanding of human disease mechanisms and their 
evolution. 
 
Overview of Chapter 1 
The recent expansion of whole-genome sequence data available from diverse 
animal lineages provides an opportunity to investigate the evolutionary origins of specific 
classes of human disease genes. Previous studies have observed that human disease genes 
are of particularly ancient origin. While this suggests that many animal species have the 
potential to serve as feasible models for research on genes responsible for human disease, 
it is unclear whether this pattern has meaningful implications and whether it prevails for 
every class of human disease. 
I used a comparative genomics approach encompassing a broad phylogenetic 
range of animals with sequenced genomes to determine the evolutionary patterns 
exhibited by human genes associated with different classes of disease. My results support 
previous claims that most human disease genes are of ancient origin but, more 
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importantly, I also demonstrate that several specific disease classes have a significantly 
large proportion of genes that emerged relatively recently within the metazoans and/or 
vertebrates. An independent assessment of the synonymous to non-synonymous 
substitution rates of human disease genes found in mammals reveals that disease classes 
that arose more recently also display unexpected rates of purifying selection between 
their mammalian and human counterparts. 
My results reveal the heterogeneity underlying the evolutionary origins of (and 
selective pressures on) different classes of human disease genes. For example, some 
disease gene classes appear to be of uncommonly recent (i.e., vertebrate-specific) origin 
and, as a whole, have been evolving at a faster rate within mammals than the majority of 
disease classes having more ancient origins. The novel patterns that I have identified may 
provide new insight into cases where studies using traditional animal models were unable 
to produce results that translated to humans. Conversely, I note that the larger set of 
disease classes do have ancient origins, suggesting that many non-traditional animal 
models have the potential to be useful for studying many human disease genes. Taken 
together, these findings emphasize why model organism selection should be done on a 
disease-by-disease basis, with evolutionary profiles in mind. The work presented in 
Chapter 1 was previously published (Maxwell et al. 2014). 
 
Overview of Chapter 2 
MicroRNAs play a vital role in the regulation of gene expression and have been 
identified in every animal with a sequenced genome examined thus far, except for the 
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placozoan Trichoplax. The genomic repertoires of metazoan microRNAs have become 
increasingly endorsed as phylogenetic characters and drivers of biological complexity. 
In this chapter, I report the first investigation of microRNAs in a species from the 
phylum Ctenophora. I use short RNA sequencing data and the assembled genome of the 
lobate ctenophore Mnemiopsis leidyi to show that this species appears to lack any 
recognizable microRNAs, as well as the nuclear proteins Drosha and Pasha, which are 
critical to canonical microRNA biogenesis. This finding represents the first reported case 
of a metazoan lacking a Drosha protein. 
Recent phylogenomic analyses suggest that Mnemiopsis is the earliest branching 
metazoan lineage. If this is true, then the origins of canonical microRNA biogenesis and 
microRNA-mediated gene regulation may postdate the last common metazoan ancestor. 
Alternatively, canonical microRNA functionality may have been lost independently in 
the lineages leading to both Mnemiopsis and the placozoan Trichoplax, suggesting that 
microRNA functionality was not critical until much later in metazoan evolution. The 
work presented in Chapter 2 was previously published (Maxwell et al. 2012). 
 
Overview of Chapter 3 
MicroRNAs (miRNAs) regulate gene expression by binding to partially 
complementary sequences on target mRNA transcripts, thereby inhibiting their 
translation. Genomic variants can alter miRNA regulation by modifying miRNA target 
sites, and multiple human disease phenotypes have been linked to such miRNA target site 
variants (miR-TSVs). However, identifying functional miR-TSVs systematically is 
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difficult due to high false positive rates; functional miRNA recognition sequences can be 
as short as six nucleotides in length and the human genome encodes thousands of 
miRNAs. Furthermore, miR-TSV prediction methods for analyzing large-scale clinical 
genomic data sets that are becoming increasingly commonplace have not yet been 
developed. 
In this chapter, I present an open-source tool called SubmiRine that is designed to 
efficiently predict miR-TSVs from variants identified in novel clinical genomic data sets. 
SubmiRine also allows for the prioritization of predicted miR-TSVs according to their 
relative probability of being functional. I present the results of SubmiRine using 
integrated clinical genomic data from a large-scale cohort study on chronic obstructive 
pulmonary disease (COPD), making a number of high-scoring, novel miR-TSV 
predictions. I also demonstrate SubmiRine’s ability to predict and highly prioritize known 
miR-TSVs that have undergone experimental validation in previous studies. The work 
presented in Chapter 3 is under review for publication (Maxwell et al. submitted). 
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CHAPTER 1. EVOLUTIONARY PROFILING REVEALS HETEROGENEOUS 
ORIGINS OF CLASSES OF HUMAN DISEASE GENES: IMPLICATIONS FOR 
MODELING DISEASE GENETICS IN ANIMALS 
Introduction 
The set of human genes implicated in Mendelian diseases are of particular interest 
in biomedical research. These “disease genes” contain mutations that increase 
susceptibility to a disease phenotype, but are tolerated well enough as to not cause 
lethality in early developmental stages. Studies have demonstrated that disease genes are 
a non-random subset of all human genes (Feldman et al. 2008; Goh et al. 2007; Domazet-
Loso & Tautz 2008; Cai et al. 2009; Lopez-Bigas 2004; Dickerson & Robertson 2012). 
For example, human disease genes tend to be non-essential, having relatively few 
interacting partners; as a result, disease genes are often located on the periphery of gene 
networks (Feldman et al. 2008; Goh et al. 2007). From an evolutionary perspective, 
human disease genes tend to have particularly ancient origins (Domazet-Loso & Tautz 
2008; Cai et al. 2009; Lopez-Bigas 2004; Dickerson & Robertson 2012), suggesting that 
disease-causing mutations are more often identified in “older” genes. Human disease 
genes also display unique patterns of purifying selection, duplication history, and tissue-
specific expression (Cai et al. 2009; Dickerson & Robertson 2012; Feldman et al. 2008).  
The implications of these observations in the context of how human disease 
research is conducted are not well understood. One proposition is that the tendency for 
disease genes to be of ancient origins implies that they are often functionally conserved 
across many animal lineages. Consequently, it may be possible to study disease genes in 
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a broad spectrum of animal models. For example, a previous study estimated that over 
90% of disease genes emerged prior to the divergence of bilaterally symmetrical 
(bilaterian) animals (Domazet-Loso & Tautz 2008). This evolutionary divergence, which 
dates back over 600 million years (Peterson et al. 2008), is marked by rapid innovation 
that gave rise to the vast majority of animal species living today. Another study noted that 
~44% of a curated subset of disease genes were found to have orthologs in the yeast 
Saccharomyces cerevisiae (Rubin et al. 2000; Sullivan & Finnerty 2007). 
The use of traditional model organisms that are relatively closely related to 
humans (including primates, mice, and, more recently, zebrafish) has been quite 
successful in yielding results that can translate to humans (Berghmans et al. 2005; 
Ratajczak & Muglia 2008; Norton & Bally-Cuif 2010; Murphy & Lesch 2008; C. Y. 
Chen et al. 2009a; Lanford et al. 2010), but more distantly related animals have also been 
utilized for studying various human disease genes and diseases. Pharmaceutical 
companies have successfully used Caenorhabditis elegans (Kaletta & Hengartner 2006) 
and Drosophila melanogaster (Pandey & Nichols 2011) in drug discovery research. The 
sea anemone Nematostella vectensis is becoming recognized as a strikingly useful model 
organism, despite being a non-bilaterian animal even more remotely related to humans 
than worms and flies (Sullivan & Finnerty 2007; Reitzel et al. 2012; Martindale & P. N. 
Lee 2013). Most recently, major expansions to the inventory of whole-genome sequences 
from species across the animal tree have fueled the effort to identify and develop new 
model systems, with some of these species beginning to demonstrate real potential for the 
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study of human disease (Reitzel et al. 2012; Pang & Martindale 2008a; Pang & 
Martindale 2008b; Plickert et al. 2012). 
In part, efforts to introduce new model systems to the standard experimental 
repertoire are motivated by the fact that some traditional animal models more closely 
related to humans present significant obstacles to researchers, including high cost, slow 
generation time, and complexity in measuring phenotypes. Increasingly, ethical issues are 
also preventing the use of our closest mammalian relatives as model organisms. In June 
2013, the National Institutes of Health announced the retirement of chimpanzees in their 
research facilities following a report from the Institute of Medicine demonstrating that 
advances in biomedical research have enabled the use of alternative model organisms in 
studies traditionally utilizing chimpanzees (Institute of Medicine (US) and National 
Research Council (US) Committee on the Use of Chimpanzees in Biomedical and 
Behavioral Research et al. 2011). These advances are a testament to the advent of new 
technologies that allow for the direct manipulation of a model organism’s genetics 
(Rongvaux et al. 2011; Jucker 2010; M. de Jong & Maina 2010); they also demonstrate 
the power of comparative genomic techniques in improving our understanding of animal 
genetics as a whole. Although there are logistical advantages to using simpler 
invertebrate animals as models, many questions remain regarding their suitability for 
human disease research. The choice of model organism for any given study has many 
contributing factors; primarily, a model organism must have analogous biological 
properties to the particular human condition of interest and must also be experimentally 
tractable. The extensive number of animal species with completed genome sequences 
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provides a natural platform for a fresh analysis of the evolutionary distribution of disease 
genes for this purpose. 
Previous studies on the origins of human disease genes found that the early 
animal lineages correspond to periods of rapid innovation for human disease genes 
(Feldman et al. 2008; Domazet-Loso & Tautz 2008; Goh et al. 2007; Cai et al. 2009; 
Dickerson & Robertson 2012), but these studies were conducted prior to the availability 
of whole-genome sequence in many of these lineages. Recent efforts to sequence the 
genomes of species representing the earliest-evolving animal phyla such as ctenophores 
(Mnemiopsis leidyi (J. F. Ryan et al. 2013)), sponges (Amphimedon queenslandica 
(Srivastava et al. 2010)),  placozoans (Trichoplax adhaerens (Srivastava et al. 2008)), and 
cnidarians (Nematostella vectensis (Putnam et al. 2007)), as well as their closest non-
animal relatives (e.g., the unicellular filasterian Capsaspora owczarzaki and the 
unicellular choanoflagellates Monosiga brevicollis and Salpingoeca rosetta) (Ruiz-Trillo 
et al. 2007), have increased our understanding of what shaped the evolution of 
multicellularity in animals and, by extension, what biological and physiological processes 
are universal to animals. Given these new data, we are now able to more thoroughly 
investigate the distribution of human disease genes across the Metazoa.  
The utility of distantly related animal models for human disease research depends 
on the disease of interest and whether or not it is feasible to study in a particular 
organism. However, this distinction is not easy to make, as it requires determining the 
point in evolutionary time when a process related to human disease became functionally 
conserved. Often, this determination is made through identification of sequence orthologs 
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which, under the assumptions of the “orthology-function conjecture” (Gabaldón & 
Koonin 2013), would imply that sequence similarity across species is synonymous with 
functional similarity. However, there are caveats to the orthology-function conjecture; 
while it tends to hold true as a generalized, genome-scale approach for assigning function 
to newly sequenced genes, contradictory cases certainly arise (Gabaldón & Koonin 
2013). Furthermore, determining whether a human Mendelian disease phenotype can be 
replicated in a distant ortholog may require consideration of characteristics beyond 
functional similarity, such as mutational effects and species-specific adaptation. Thus, 
while orthology is useful for identifying candidate genes of interest in a model organism, 
other context-specific conditions still need to be considered. Nevertheless, while the point 
in evolutionary time in which a disease gene emerged may not be equivalent to when it 
acquired its disease-related function, these two time points are likely correlated. Given 
this, the relative age of a disease gene class can be used as a criterion in selecting an 
appropriate species in which to study relevant underlying processes. 
No study to date has analyzed the evolutionary distributions of specific classes of 
human disease genes. Rather, existing studies have focused on conservation at the levels 
of single genes, cancer-related genes (Domazet-Loso & Tautz 2010), or on the superset 
of all human disease genes (Domazet-Loso & Tautz 2008; Podder & Ghosh 2010; 
Dickerson & Robertson 2012). However, different disease classes exhibit diverse 
properties in gene interaction networks (Goh et al. 2007); this suggests that, collectively, 
disease gene classes are not homogeneous. I hypothesized that disease gene classes also 
have heterogeneous evolutionary origins and pressures. A number of recent high-profile 
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cases support this perceived heterogeneity; incongruities have been encountered between 
humans and closely related traditional animal models at both the genotypic and 
phenotypic levels for specific disease genes and classes, resulting in research findings 
that could not be translated into new treatments for human disease (Rongvaux et al. 2011; 
Seok et al. 2013; Jucker 2010; Martin et al. 2010; M. de Jong & Maina 2010; C. Y. Chen 
et al. 2009a; Schäfer & Kolkhof 2008; Böhm et al. 2009; van der Worp et al. 2010; 
Tsilidis et al. 2013). 
In this work, I have leveraged the vast amount of new whole-genome sequence 
data from a broad phylogenetic range of animals to analyze the evolutionary distributions 
of specific classes of human disease genes. I set out to accomplish three main goals: (1) 
to increase the resolution of evolutionary emergence patterns of human disease genes in 
animals, (2) to determine whether any specific disease classes show unique patterns of 
evolution, and (3) to perform an initial investigation into whether evolutionary metrics 
can help inform the process of selecting appropriate animal models (including “non-
traditional” species) for studying the underlying genetics of specific human disease 
classes, citing a handful of recently reported cases where results generated in animal 
models could not be translated into humans. 
Results 
Evolutionary Distribution of All Human Disease Genes 
The OMIM database (Hamosh et al. 2005) contains a manually curated set of 
human genes that are implicated in the causation of human genetic or genomic disorders. 
OMIM flags the highest confidence gene-disease associations as a “type 3” phenotype. 
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These represent particular disease phenotypes in which the underlying molecular basis is 
known and has been mapped to a specific gene; at the time of this writing, this 
encompasses 3096 human genes. To analyze the distribution of these disease genes 
across animals and their closest relatives (unicellular filasterians and choanoflagellates), I 
overlaid the disease genes onto clusters of orthologous genes that were generated using a 
phylogenetically aware ortholog clustering algorithm with predicted protein sequences 
from 23 species (including human) whose genomes have been sequenced (see Methods). 
2727 of the OMIM disease genes were present in the clusters after filtering out genes that 
did not map to ENSEMBL proteins (270) or did not successfully cluster (99). Thus, using 
the clusters that contain at least one human OMIM disease gene, I obtain an evolutionary 
distribution of that disease gene based on the presence or absence of an ortholog in each 
of the 23 species. 
I then analyzed the patterns in which these disease genes emerged within the 
Metazoa using phylostratification, a process by which genes are placed into major 
taxonomic groups (“phylostrata”) according to their inferred evolutionary emergence 
point (Domazet-Loso et al. 2007). I used the presence/absence distributions within 
clusters to bin disease genes into phylostrata based upon the lineage in which they first 
appeared in the analysis. Henceforth, I refer to each phylostratum by the most basal 
classification that it includes, although phylostrata are, in fact, hierarchical. My analysis 
considers only species as distant as the Filozoa (i.e., animals and their closest unicellular 
relatives), so this placement does not necessarily identify the emergence of a “founder 
gene” but, rather, characterizes the evolutionary patterns of gene families within and 
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around animals. Figure 1.1 shows the full distribution of orthologs to the 2727 OMIM 
genes and the corresponding phylostratification, representing the evolutionary signature 
of all human disease genes. 
In comparison to the superset of all human genes, I identify some of the same 
trends noted in previous studies (Domazet-Loso & Tautz 2008; Sullivan & Finnerty 
2007; Rubin et al. 2000). Specifically, I observe that more than half of human disease 
genes are of ancient, pre-animal origins (52%), a number significantly larger than would 
be expected if disease genes were merely a random subset of all human genes (42.7%, p 
= 1.2 x 10-25 per one-tailed hypergeometric test; see Table 1.1 and Figure 1.2). I also 
observe that surprisingly few human disease genes have origins within the vertebrates or 
later (14.7%), as compared to 25.9% of all human genes (p = 2.7 x 10-50 per one-tailed 
hypergeometric test). Notably, my inclusion of newly available whole-genome sequence 
data from the earliest animal lineages suggests that many human disease genes emerged 
with the first animals (16.2%). As with the pre-Metazoan set, this early animal gene set 
also represents a significantly larger proportion than would be expected based on all 
human genes (13.9%, p = 1.4 x 10-4 per one-tailed hypergeometric test). Overall, the 
complete phylostratigraphic distribution of human disease genes versus all human genes 
shows a significantly ancient skew (p = 2.2 x 10-16 per χ2 two-sample test; see Table 1.1 
and Figure 1.2). !  
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Figure 1.1. Distribution of human disease gene orthologs. 
Heat maps showing the presence (green) or absence (red) of an ortholog for a given human disease gene from OMIM 
(rows) within each species (columns). All 2727 human disease genes from OMIM are displayed. Major phylogenetic 
divergence events define the six phylostratigraphic bins indicated in the phylogenetic species tree. Rows are ordered 
such that disease genes first appearing in each phylostratigraphic bin (indicated by black lines) are clustered, with the 
corresponding percentage of the total for each cluster projected on the stacked bar on the left. 
Hs, Homo sapiens; Gg, Gallus gallus; Xt, Xenopus tropicalis; Dr, Danio rerio; Ci, Ciona intestinalis; Bf, 
Branchiostoma floridae; Sp, Strongylocentrotus purpuratus; Lg, Lottia gigantea; Ct, Capitella teleta; Hr, Helobdella 
robusta; Sm, Schistosoma mansoni; Pp, Pristionchus pacificus; Ce, C. elegans; Dm, D. melanogaster; Dp, Daphnia 
pulex; Is, Ixodes scapularis; Hm, Hydra magnipapillata; Nv, N. vectensis; Ta, T. adhaerens; Aq, A. queenslandica; Ml, 
M. leidyi; Mb, M. brevicollis; Co, C. owczarzaki. ! !
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Gene Set Filozoa Metazoa Parahoxozoa Bilateria Deuterostomia Vertebrata Total 
All Human Genes 
(22331) 9551 3102 1556 1044 1304 5774 22331 
Human Disease Genes 
(OMIM) 1419 441 200 145 120 402 2727 
IPA-annotated Human 
Disease Genes 991 321 146 103 88 290 1939 
Unannotated Human 
Disease Genes 428 120 54 42 32 112 788 
(A) Number of genes binned in each phylostratum. 
 
 
Gene Set Filozoa Metazoa Parahoxozoa Bilateria Deuterostomia Vertebrata Total 
All Human Genes 
(22331) 0.428 0.139 0.070 0.047 0.058 0.259 1 
Human Disease Genes 
(OMIM) 0.520 0.162 0.073 0.053 0.044 0.147 1 
IPA-annotated Human 
Disease Genes 0.511 0.166 0.075 0.053 0.045 0.150 1 
Unannotated Human 
Disease Genes 0.543 0.152 0.069 0.053 0.041 0.142 1 
(B) Percentage of genes binned in each phylostratum. 
 
Table 1.1. Distributions of genes by phylostrata. ! !
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Figure 1.2. Origins of human disease genes versus all human genes. 
Comparison of the evolutionary distribution of the human disease gene subset (orange) versus all human genes (y=0; 
data not shown). χ2 two-sample test, p = 2.2 x 10-16. Numbers of genes binned into individual phylostrata were further 
compared, showing over-representations in the Filozoa and Metazoa phylostrata and under-representations in the 
Deuterostomia and Vertebrata phylostrata (hypergeometric test; *** p < 1.0 x 10-20, ** p < 0.001, * p < 0.01). !  
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Species-specific Human Disease Gene Ortholog Content 
Given the ancient origins of the majority of the human disease gene set, I 
surveyed the total human disease gene ortholog content in the genomes of each species 
included in my analysis to assess their relative similarity to humans and, conversely, their 
propensity for gene loss and lineage-specific divergence. Even the animal phyla most 
distantly related to humans – ctenophores and sponges (represented by Mnemiopsis and 
Amphimedon) – contain orthologs to about half of all human disease genes (51.6% and 
56.3%, respectively; see Figures 1.1 and 1.3). Immediately outside of the Metazoa, these 
percentages drop to 39.4% (for the choanoflagellate Monosiga) and 41.8% (for the 
filasterian Capsaspora). My analysis identified a strikingly high number of human 
disease gene orthologs in the non-bilaterian cnidarian Nematostella (67.8%), consistent 
with previously reported findings that its genome is quite complex (Putnam et al. 2007; 
Martindale & P. N. Lee 2013; Sullivan & Finnerty 2007). Comparatively, the average 
number of human disease gene orthologs present in the vertebrate (D. rerio, X. tropicalis, 
and G. gallus) and invertebrate (S. purpuratus, B. floridae, and C. intestinalis) 
deuterostomes that I studied was 93% and 73%, respectively. 
I do not observe a steady increase in the number of orthologs identified relative to 
evolutionary divergence times from the human lineage, suggesting lineage-specific loss 
and divergence rates are not strictly dependent on evolutionary relation to humans. The 
nematode C. elegans contains orthologs to only 57.4% of human disease genes, a 
proportion smaller than Nematostella and hardly larger than the earliest branching 
metazoans, despite having diverged over 100 million years afterwards. This trend is also 
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observed to a lesser degree in a few other protostomes, including the fruit fly Drosophila, 
whose percentage of observed disease gene orthologs is 64.2%. It is well known that the 
popular protostome models C. elegans and D. melanogaster have lost a number of genes 
important to human biology (Kortschak et al. 2003; Raible & Arendt 2004; Putnam et al. 
2007; Sullivan & Finnerty 2007). However, it is not immediately obvious whether most 
of these losses are shared amongst other protostomes, or whether they tend to be 
conserved in earlier-evolving phyla. Using our cluster analysis, we investigated how this 
particular set of disease genes is distributed with respect to the genomes of other animal 
species. 
Figure 1.4 shows a heat map of OMIM genes in which an ortholog is absent from 
both C. elegans and D. melanogaster (863 out of 2727, or 31.6%). From these 863 
missing genes, 292 are present in more distant non-bilaterian lineages, of which 223 are 
present in at least two such non-bilaterian species. This illustrates that nearly one-third of 
all human disease genes are absent (or highly derived) in both of these popular model 
organisms; in turn, one-third of these potentially represent gene losses and are not just the 
result of more recent evolutionary innovation. This analysis suggests that roughly 10% of 
all human disease genes could potentially be better-studied in selected non-bilaterian 
species than in either C. elegans or D. melanogaster, with Nematostella being an obvious 
candidate. For example, the breast cancer susceptibility gene BRCA2 and the BRCA1-
interacting protein BRIP1 are identified in every species studied except for the three 
protostomes D. melanogaster, C. elegans, and P. pacificus, with BRCA2 additionally 
being absent in L. gigantea; BRCA2 was previously identified to be well conserved in 
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Nematostella (Sullivan & Finnerty 2007). While these remote animal species are less 
complex than humans, it is quite possible that studying the most distant forms of these 
genes would reveal insights into the most basic functions they evolved to perform and, by 
extension, their relationship to human disease. !  
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Figure 1.3. Human disease gene content per species by phylostratigraphic method. 
Number of human disease gene (OMIM) orthologs and RBHs identified in each species studied, with overlap between 
the two indicated. Zeros indicate unreliable overlap counts due to mismapped sequence identifiers (Dp, Ct, and Xt) or 
species not contained in the clusters of orthologous genes (Sc). 
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Figure 1.4. Lineage-specific loss/divergence of human disease genes in C. elegans and D. melanogaster. 
The subset of human disease genes (863 of 2727; see Figure 1.1) absent in both D. melanogaster and C. elegans 
(indicated by the solid black box), one-third of which are possible gene losses (292) due to their presence in a more 
distant phylostratum (dashed black box).  
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Identification of Disease Classes with Unique Origins 
On the one hand, my analysis has provided additional evidence that the majority 
of the human disease gene set has particularly ancient origins. I have expanded upon the 
notion that many of our most remote animal relatives contain large proportions of human 
disease gene orthologs. On the other hand, it is unlikely that all disease classes follow 
this same evolutionary model. I aimed to identify disease classes and disease-related 
biological processes that do not conform to the evolutionary profile exhibited by the 
superset of all disease genes. Currently, there is no “gold standard” disease gene 
annotation process that provides appreciable statistical power for analyzing these kinds of 
evolutionary profiles. While the OMIM database (Hamosh et al. 2005) does provide 
disease annotations for individual genes, I did not utilize these annotations because they 
are not guaranteed to be consistent across the database and are not widely standardized. 
Instead, I annotated the OMIM disease gene set with “level-1” and “level-2” functional 
classifications generated through the use of the Ingenuity Pathway Analysis (IPA) 
software suite (Ingenuity Systems®, http://ingenuity.com). IPA classifications are based 
on a curated, literature-derived knowledge base and have multiple levels of specificity; I 
chose to use the top two classification levels, corresponding to functional categories 
(level-1) and subcategories (level-2). In order to select for IPA classifications related to 
disease processes, I selected only those classifications whose occurrences were enriched 
in the disease gene set (Fisher’s exact test; p < 0.05, Benjamini-Hochberg-corrected). 
This method does not require that every assigned annotation reflect the same disease-
causing mutation as reported in OMIM. Rather, a set of high-confidence annotations for 
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diseases and disease-related processes is produced, for which a substantial set of known 
human disease genes play a role. 
For each enriched classification (and the corresponding subset of disease genes), I 
replicated the cluster-based phylostratigraphic analysis to compare the evolutionary 
distribution of the annotated genes to the distribution produced using all human disease 
genes from OMIM (see Figure 1.1). Disease-related subsets (referred to as “disease 
classes” throughout) displaying a statistically significant deviation in their complete 
phylostratigraphic distribution (Fisher’s exact test, 2 x 6 contingency table; p < 0.05, 
Bonferroni-corrected) were identified and analyzed. Of the 77 level-1 annotations 
considered, 48 (representing 62% of tested disease classes) were not found to 
significantly deviate from the null model (i.e., the pattern observed for all OMIM genes 
as a whole). This included annotations for cancer, neurological diseases, and metabolic 
diseases. The results suggest that the majority of human diseases have very ancient 
origins, consistent with what I observed for the superset of all disease genes. However, 
the other 29 annotations (representing 38% of tested disease classes) were all under-
represented in the Filozoa phylostratum (Figure 1.5), appearing more recently within the 
Metazoa than would be expected based on the null distribution. The same pattern is 
observed when considering level-2 annotations, in which 113 out of 500 classifications 
(22.6%) were found to significantly deviate from the null model, all exhibiting an under-
representation in the Filozoa. Thus, there do not appear to be any disease classes with a 
significantly more ancient origin than the null distribution (i.e., with over-representation 
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of pre-metazoan genes), but there is a substantial set of disease classes that are 
characterized by sets of genes from more recent metazoan-specific innovations. 
To ensure that these results were not an artifact of the IPA annotation process, 
which could potentially be biased towards more recently evolved genes, I compared the 
distributions of the set of disease genes that received no annotation (788) as well as the 
set that received at least one annotation (1939) to the null model of all OMIM genes. 
Both of these sets produce an evolutionary distribution almost identical to the superset of 
all OMIM genes (Fisher’s exact test, 2 x 6 contingency table; p = 0.93 and p = 0.99, 
respectively; see Table 1.1), suggesting that the IPA annotation process does not produce 
an evolutionary bias. Therefore, I can conclude that the 29 more recently emerging 
disease classes I have identified are exceptions to the ancient trend exhibited by the 
superset of all diseases, substantiating the concern that many diseases do not adhere to 
this overly generalized model of conservation. !  
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Figure 1.5. Disease classifications with non-conforming evolutionary origins. 
The 29 “level-1” disease-related annotations corresponding to genes with significantly deviating evolutionary 
distribution from the null model (“All OMIM”, see Figure 1.1 and Methods). Individual phylostratigraphic bins having 
over- or under-representation compared to the null model (Fisher’s exact test, 2 x 2 contingency table; p < 0.05) are 
indicated. Disease classes are hierarchically clustered by Euclidean distance-based similarity. 
RespSys (Respiratory System Development and Function), AudVeSys (Auditory and Vestibular System Development 
and Function), InfectDis (Infectious Disease), ImCelTra (Immune Cell Trafficking), InflamDis (Inflammatory 
Disease), CellSign (Cell Signaling), Hematop (Hematopoiesis), ImmuDis (Immunological Disease), C2CSign (Cell-to-
Cell Signaling and Interaction), EndocSys (Endocrine System Disorders), VitMinMet (Vitamin and Mineral 
Metabolism), HemaSys (Hematological System Development and Function), InflamRes (Inflammatory Response), 
HepaSys (Hepatic System Disease), LymphTis (Lymphoid Tissue Structure and Development), HemaDis 
(Hematological Disease), CardioDis (Cardiovascular Disease), CellMove (Cellular Movement), ConnTis (Connective 
Tissue Disorders), NervSys (Nervous System Development and Function), SkeMuSys (Skeletal and Muscular System 
Development and Function), GeneExp (Gene Expression), CellDev (Cellular Development), TisMorph (Tissue 
Morphology), TisDev (Tissue Development), OrgDev (Organismal Development), OrganMor (Organ Morphology), 
OrganDev (Organ Development), EmbryDev (Embryonic Development). A dagger (†) denotes annotations not 
identified as significant with an alternative phylostratification method based on reciprocal BLASTP (see Methods). !  
!!
26 
Novel Signatures of Disease Class Evolutionary Origins 
Further analysis of the disease class-specific gene subsets revealed four recurring 
evolutionary patterns. The four patterns include the expected distribution displayed by all 
human disease genes and the majority of disease classes, with three of them being novel 
patterns that I refer to as “evolutionary signatures.” The first novel signature has genes 
evolving at expected rates between the emergence of metazoans and the deuterostomes, 
but appearing much more frequently than expected in the vertebrates and much less 
frequently prior to metazoans (Figure 1.6A). I term these the “vertebrate-specific” disease 
classes, which are the most recently evolved, and includes nine classifications such as 
Inflammatory Disease (InflamDis), Inflammatory Response (InflamRes) and Infectious 
Disease (InfectDis). For example, various sets of cytokines and their receptors were 
binned in the vertebrate lineage and linked to inflammatory diseases, including 
chemokines (CCLs), interleukins (ILs and ILRs), interferons (IFNGs and IFNGRs), and 
immunoglobulins (FCGRs). This group also includes some more ancient genes, such as 
sodium channel transporters (SCNs) and solute carriers (SLCs), perhaps representing 
ancient genes co-opted into the inflammatory response pathways at some point within 
vertebrate evolution. 
The second novel signature (Figure 1.6B) is characterized by a set of disease 
classes that are under-represented outside of animals and over-represented in the early 
animal phyla (but not in the deuterostomes or vertebrates); I called these the “early 
metazoan” disease classes. This group of ten contains many developmental processes 
inherent to animals, including Embryonic Development (EmbryDev), Organ 
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Development (OrganDev), and Organ Morphology (OrganMor), as well as processes 
related to the development and function of the Nervous System (NervSys), Skeletal and 
Muscular System (SkeMuSys), Respiratory System (RespSys), and the Auditory and 
Vestibular System (AudVeSys). While some of these systems may not have evolved in 
their entirety during the earliest stages of animal evolution, the data indicate that 
necessary components of these systems evolved within the Metazoa rather than prior to it, 
and more likely arose well before the evolution of the vertebrates. 
The third signature (Figure 1.6C) seemingly represents an overlap between the 
“vertebrate-specific” and “early metazoan” signatures; I call these the “multi-stage 
metazoan” disease classes. This group of ten classes is distinguished by an under-
representation outside the Metazoa and over-representations of lesser magnitude in both 
the non-bilaterian and vertebrate lineages. A number of these classifications include 
disease processes related to blood and the cardiovascular system, namely Cardiovascular 
Disease (CardioDis), Hematopoiesis (Hematop), Hematological Disease (HemaDis) and 
Hepatic System Disease (HepaSys). These signatures appear to have multi-modal 
distributions, indicating a more complex evolutionary history where different components 
of biological processes and diseases emerged at different periods in animal evolution, 
coinciding with major genomic innovation events. !  
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Figure 1.6. Distinct evolutionary signatures of disease classes. 
Comparison of the 29 “level-1” disease-related annotations identified as having a statistically significant evolutionary 
distribution (see Figure 1.5 and Methods), displayed relative to the distribution of the null model (all OMIM genes). 
Annotations are separated into signatures for A) vertebrate-specific, B) early metazoan, and C) multi-stage metazoan 
disease classifications. Only statistically significant over/under-representations of points within individual 
phylostratigraphic bins are plotted as non-zero (Fisher’s exact test, 2 x 2 contingency table; p < 0.05), corresponding to 
those denoted in Figure 1.5. Points marked with an asterisk (*) denote over/under-representations where p < 6.5 x 10-4 
(p < 0.05, Bonferroni corrected for bin-specific comparisons). !  
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Differing Rates of Purifying Selection Act on Disease Classes of Different Age 
My phylostratigraphic analysis of disease gene age suggests that most disease 
genes evolved before or within the earliest vertebrate lineages. I estimate that >96% of 
the disease genes emerged before the divergence of zebrafish (D. rerio; see Figure 1.1). 
This is of particular importance given that there has been rapid and remarkable success in 
developing zebrafish into a standard animal model, especially after the sequencing of its 
genome (Howe et al. 2013). However, recent cases of studies involving traditional model 
organisms that failed to produce results that can translate to humans (Seok et al. 2013; 
Martin et al. 2010; C. Y. Chen et al. 2009a; Schäfer & Kolkhof 2008; Böhm et al. 2009; 
Jucker 2010; M. de Jong & Maina 2010; van der Worp et al. 2010; Tsilidis et al. 2013) 
suggest that consideration of disease gene age alone (or the identification of an ortholog) 
may not be sufficient to rationalize the use of an organism as an appropriate model for 
studying human disease. Specifically, these reports have found inconsistencies relative to 
the human phenotype when studying inflammatory diseases in mice (Seok et al. 2013), 
certain immune responses in non-primates (C. Y. Chen et al. 2009a), and acute 
myocardial infarction drug candidates in dogs and rabbits (Schäfer & Kolkhof 2008). My 
analysis identified both inflammatory disease (InflamDis) and immunological disease 
(ImmuDis) as being grouped within the vertebrate-specific evolutionary signature, and 
various disorders related to blood and the cardiovascular system matching the multi-stage 
metazoan evolutionary signature [e.g., cardiovascular disease (CardioDis)]. As these two 
signatures are characterized by the over-representation of vertebrate-specific genes and 
under-representation of pre-metazoan genes, I can infer that these are the most recently 
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evolved disease class signatures. Based on this inference, I hypothesize that a correlation 
exists between the relative genetic age of a disease and the evolutionary distance at which 
a particular model organism would be useful. 
I posited that the presence of an unusual degree of purifying selection between a 
class of human disease genes and their orthologs in a model species may indicate 
potential problems for studying that particular disease class in that model organism. It has 
been shown previously that, in general, older genes evolve more slowly than younger 
ones (Wolf et al. 2009). However, it has also been shown that disease genes do not follow 
this trend; both younger and older disease genes appear to evolve slowly, at rates more 
similar to that of older genes (Cai et al. 2009). Thus, I tested how different classes of 
disease genes behave by independently analyzing the selective pressures occurring on 
genes from each of the disease classes. I focused specifically on mammalian and primate 
species to see if a relationship exists between my identified signatures based on disease 
gene age and their evolutionary conservation within mammals. Sequence data were 
collected from nine well-characterized species: Canis lupus familiaris (dog), Felis catus 
(cat), Rattus norvegicus (rat), Mus musculus (mouse), Oryctolagus cuniculus (rabbit), 
Otolemur garnetti (bushbaby), Callithrix jacchus (marmoset), Macaca mulatta 
(macaque), and Pan troglodytes (chimpanzee).  
For each disease class, I analyzed the distribution of dN, dS, and dN/dS values for 
each disease gene within each of these mammalian species (see Methods). This analysis 
was restricted to mammals in order to maintain reliable dS rate estimates that can become 
saturated over larger evolutionary distances. I then compared these values to those 
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calculated for the distribution of all 2727 human disease genes described above (Mann-
Whitney U two-tailed test; p < 0.05, Bonferroni-corrected). This process enabled me to 
identify, for each mammalian model organism, disease classes having evolutionary rates 
that deviate significantly from the distribution observed for all human disease genes. To 
visualize and quantify positive or negative deviations, median values (with 95% 
confidence intervals) of the distributions for each metric were computed for each class of 
disease genes. Overall, the dS rates tended to follow the distribution observed for all 
human disease genes, but there were multiple cases of statistically significant deviations 
in dN rates. Henceforth, we only refer to the dN/dS ratio as it summarizes both statistics, 
noting that changes in dN/dS are predominately driven by changes in dN rates. Figure 1.7 
shows the median dN/dS metric for each disease gene class found to significantly deviate 
from the distribution observed for all human disease genes in each mammalian species. 
The disease classes themselves have been grouped based on their age-based evolutionary 
signature identified via phylostratigraphic analysis (i.e., vertebrate-specific, early 
metazoan, or multi-stage metazoan; see Figure 1.6). 
Generally, the vertebrate-specific disease classes (Figures 1.6A and 1.7A) show 
weaker purifying selection than expected (i.e., median dN/dS closer to 1 as compared to 
all human disease genes) in the mammalian species considered, whereas the early-
metazoan disease classes (Figures 1.6B and 1.7B) show stronger purifying selection than 
expected (i.e., median dN/dS closer to 0 as compared to all human disease genes). The 
magnitude of these trends varies for disease classes within each of the previously 
described evolutionary signatures. For example, the infectious disease class exhibits the 
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largest over-representation of vertebrate-specific genes (Figure 1.6A); it also 
demonstrates the weakest degree of purifying selection in all mammalian species 
considered (Figure 1.7A). On the other end of the spectrum, vertebrate-specific disease 
classes that do not exhibit as large of an over-representation of vertebrate-specific genes 
(such as the connective tissue disorders and cellular movement classes) do not 
significantly deviate from the superset of all human disease genes by the dN/dS metric. In 
most cases, the deviations showing significantly weak purifying selection (i.e., dN/dS 
closer to 1) more often occur in mammals of more distant relation to humans, supporting 
the logical conclusion that some disease classes are well conserved only in our closest 
animal relatives, but not necessarily in all mammals. I note that the human inflammatory 
disease genes tend to show weak purifying selection rates in mammals, with the deviation 
being statistically significant only in rat and mouse; this is consistent with my hypothesis 
that degree of purifying selection is related to appropriate model organism choices (Seok 
et al. 2013). 
The multi-stage metazoan disease gene classes (Figure 1.6C and 1.7C) again 
appear to represent a combination of the vertebrate-specific and early-metazoan classes; 
some show slightly weaker purifying selection and some show slightly stronger purifying 
selection relative to all human disease genes, but the magnitudes of these differences are 
not considered statistically significant. The set of disease classes that were considered 
non-deviating from all human disease genes via phylostratification generally were also 
non-deviating in dN/dS values, with a handful (8 out of 48) being under stronger 
purifying selection than all human disease genes and having patterns similar to the early-
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metazoan cases (e.g., “Behavior”, “Developmental Disorder”, “Neurological Disease”, 
and “Visual System Development and Function”). 
To determine which genes are driving the deviation patterns exhibited in Figures 
1.7A and 1.7B, I compared the dN/dS ratio distributions for all human disease genes 
between phylostrata. Only the vertebrate-specific set of human disease genes 
demonstrates a unique rate of purifying selection (significantly weaker than “older” 
genes), whereas all disease genes with pre-vertebrate origins are essentially 
indistinguishable from each other by this metric (see Methods and Figure 1.8). This 
explains why disease classes with high proportions of vertebrate-specific genes are, 
overall, under weaker rates of purifying selection. It is important to note that I cannot rule 
out the possibility that difficulties in identifying distant homologs of rapidly evolving 
genes could lead us to believe that they are younger. However, the stronger rates of 
purifying selection observed in the early-metazoan disease classes seem to be more 
context-specific, reflecting unique evolutionary pressures acting on these specific 
biological processes opposed to a universal pattern for all disease genes of early 
metazoan origins. This suggests that some of the human disease-related processes that 
evolved with multicellularity in the earliest animal lineages are potentially under stronger 
evolutionary constraints than those with unicellular origins. ! !
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Figure 1.7. Distinct evolutionary pressures on disease classes of different origins in popular mammalian models. 
Comparison of the distribution of human disease gene dN/dS ratios for the 29 deviating disease classes, separated 
according to their age-related signature as defined in Figure 1.6: A) vertebrate-specific, B) early metazoan, and C) 
multi-stage metazoan classes, and compared across nine mammalian species relative to the expected distribution of all 
human disease genes from OMIM. Disease classes are. Points indicate median dN/dS with 95% confidence intervals. 
Only statistically significant differences are displayed (Mann-Whitney U two-tailed test; p < 0.05, Bonferroni-
corrected). !  
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Figure 1.8. Median dN/dS of disease gene orthologs by phylostratum. 
Median dN/dS ratios for all disease genes in each phylostratum for each mammalian species considered. !  
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Discussion 
Recent additions of non-bilaterian animal species with whole-genome sequence 
data available motivated me to analyze the evolutionary origins of human disease genes, 
with a particular focus on these early periods of animal evolution. One goal of this 
analysis was to determine the potential utility of these species in modeling the genetics 
underlying specific classes of human disease. With these genomic data in hand, my 
results corroborate previous findings that the majority of human disease genes are of 
particularly ancient origins, having many more genes of pre-animal origin than would be 
expected if disease genes were a random subset of all human genes (Cai et al. 2009; 
Lopez-Bigas 2004; Domazet-Loso & Tautz 2008). Through my analysis of additional 
early metazoan genomes, we find that there is also a significant over-representation of 
early metazoan genes in the human disease gene set, suggesting that the ancient skew of 
human disease gene origins extends into the early animal lineages as well (see Figure 1.2 
and Table 1.1). 
More importantly, I have shown that not every class of human disease genes has 
ancient origins. Rather, a subset of disease classes (38% of those examined) show 
significantly more recent origins than the superset of all human disease genes, with many 
first appearing more frequently within the Metazoa and Vertebrata. I identified three 
novel evolutionary signatures from this set, all representing disease classes with over-
representations of metazoan-specific genes: the vertebrate-specific, early metazoan, and 
multi-stage metazoan. Furthermore, I show that these patterns, based on relative genetic 
age of a human disease class, are correlated with the observed rates of evolutionary 
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selective pressures (dN/dS ratios). These two observations are made on different 
evolutionary time scales, having age measured on a pre-mammalian scale and 
evolutionary pressures measured within mammals and primates. Specifically, I have 
shown that human disease genes with vertebrate-specific origins tend to be under weaker 
levels of purifying selection within mammals than human disease genes of pre-vertebrate 
origins. This result contradicts findings that younger disease genes are evolving 
particularly slowly compared to non-disease genes; they appear to more closely mimic 
the rates observed among all genes (Cai et al. 2009; Wolf et al. 2009). As a result, classes 
of human disease that contain many vertebrate-specific genes are unlikely to be as highly 
conserved in certain mammalian models as disease classes of more ancient origins. Thus 
my results may provide some insight regarding a handful of recent experimental findings 
addressing whether mice are poor models of inflammatory diseases (Seok et al. 2013) and 
if certain immune response genes can only be studied in primates or humans (C. Y. Chen 
et al. 2009a), for example. My evolutionary profiling studies identified both 
inflammatory diseases and immunological diseases as having large proportions of 
vertebrate-specific genes that are under weaker-than-expected purifying selection, 
particularly in mice and rats for inflammatory diseases and all species beyond old world 
monkeys for immunological diseases. 
Conversely, I also demonstrated that certain disease classes with many genes of 
early metazoan origins are under particularly strong rates of purifying selection within 
mammalian lineages. This suggests that some functional groups of human disease genes 
that arose at the base of the Metazoa (and the biological processes that they are 
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responsible for) have distinct evolutionary pressures. As a group, they appear to be more 
highly conserved than both older and younger human disease genes. While the 
evolutionary rates were not computed beyond the eutherian mammals (due to issues of 
mutational saturation in dS values), I speculate that this trend continues to deeper 
branches of the metazoan tree of life. 
In practice, if the distribution of dN/dS ratios for a set of human disease genes 
with orthologs in a particular species is in fact correlated with the degree to which the 
underlying disease process can be modeled, then my results indicate that disease classes 
with over-representations of vertebrate-specific genes may be harder to mimic outside of 
our closest animal relatives. However, the opposite trend is observed for disease classes 
with over-representations of genes found in the earliest metazoan lineages, which appear 
to be under particularly strict selective pressures; these disease genes may be possible to 
study in our more distantly related animal relatives. In total, my phylostratigraphic 
analysis of individual disease classifications has demonstrated that the majority of disease 
classes (62% of those examined) do have ancient origins, consistent with the distribution 
of all human disease genes. This collective evolutionary model tends to have large 
proportions of genes that pre-date animals and are well conserved within mammals. Thus, 
this majority set of disease classes may also be promising candidates to study in a more 
diverse set of animal species. 
My results imply that there may be utility in studying disease genes that have 
primarily pre-vertebrate origins in non-traditional animal models, especially in the case of 
genes known to be lost or highly derived in popular protostome models. From my 
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analysis, I estimate that as many as 10% of all human disease genes are absent or highly 
derived in both C. elegans and D. melanogaster, but have an ortholog in at least one 
more-distantly related species. These species generally have fast regeneration times, short 
life cycles, are inexpensive to culture, and can teach us about the evolutionary context of 
conserved disease genes and the most basic functions they evolved to perform. 
Nonetheless, it is important to factor in the experimental tractability of these species, 
most of which have not been developed into standard model organisms. By endorsing 
their value to human disease research through surveys such as this one, it is hoped that 
the biomedical community will give serious consideration to expanding the standard 
repertoire of model organisms to include non-bilaterian animals. While non-bilaterians 
such as sea anemones and ctenophores may not seem tractable for human gene modeling, 
efforts are currently underway to increase their utility as “emerging model organisms” 
(Reitzel et al. 2012; Pang & Martindale 2008a; Pang & Martindale 2008b; Plickert et al. 
2012). 
Conclusions 
Taken together, the patterns I have identified highlight the need for a wider 
evolutionary perspective to be considered when selecting appropriate model organisms 
for studying a particular human disease or disorder. My results indicate that a one-to-one 
comparison of the human disease gene complement in a target model organism is 
insufficient to rationalize its use as a good model. Rather, analysis of the evolutionary 
history corresponding to the entire disease process being studied, as well as establishing 
the system-wide context in which it plays a part, can be decidedly more informative. I 
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caution against over-generalizing and approaching all human disease genes as uniformly 
evolving collections of genes. This further emphasizes the need to make model organism 
choices on a case-by-case basis in consideration of evolutionary origins, experimental 
tractability, and many other context-specific factors. 
Future efforts to extend and refine my analyses could theoretically produce 
methods that could direct an investigator to a set of model species that would be well-
suited to studying a particular human disease gene or disease class. That said, there are 
many obstacles that make this difficult to achieve at the present time. First, the 
development of a standardized database or ontology for annotating disease genes would 
be necessary to enable the comparison of disease phenotypes in greater depth and 
breadth. Second, to more precisely decipher the human disease gene content and 
tractability of emerging animal models, additional sequence data from species in the 
more sparsely represented sections of the animal phylogenetic tree will be required. The 
majority of existing data from these regions are EST traces that suffer from low gene 
coverage (C. W. Dunn et al. 2008; Hejnol et al. 2009); efforts to expand these genomic 
data with high-throughput transcriptome sequencing may provide an alternative to whole-
genome sequencing for the purpose of mapping gene content (Riesgo et al. 2012). Third, 
as new genomic data continue to be generated for these distant species, my work could be 
extended with a method that more comprehensively characterizes gene family 
relationships beyond orthology, such as the methods used for the EnsemblCompara 
GeneTrees (Vilella et al. 2009) or other methods that define gene age according to more 
dynamic properties (Capra et al. 2013). To my knowledge, these methods have yet to be 
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applied with the addition of newly sequenced genomes, especially those from non-
bilaterian animal lineages. The use of a phylogenetic gene tree-based method would also 
enable the estimation of dN values beyond mammals, which appear to be the driving 
force of the dN/dS ratio deviations we have identified. Thus, despite dS value mutational 
saturation issues, it may be possible to perform an analysis of selective evolutionary rates 
of human disease genes over a larger evolutionary distance by considering dN rate 
estimates alone. Finally, in order to more thoroughly investigate cases where certain 
animal models would be inappropriate, there needs to be a platform by which negative 
results can be reported in the literature. With the addition of these hypothetical data and 
the improvement of methodologies for defining disease gene family evolution on a 
genome-wide scale, it may be possible to develop comparative genomic tools to pinpoint 
suitable animal models in a context-specific fashion. 
Methods 
Phylostratigraphic Analysis with Clusters of Orthologous Genes 
The phylostratigraphic analysis presented in this chapter was based on clusters of 
orthologous genes generated following the sequencing and annotation of the Mnemiopsis 
leidyi genome (J. F. Ryan et al. 2013). Briefly, these clusters of genes with putative 
orthology in humans and 22 other species were generated using sequence similarity based 
on BLAST and relative position in a predetermined phylogenetic species tree (see Figure 
1.1). Bit scores were assigned to hits between each pair of genes by summing those for 
initial BLASTP high-scoring segments (HSPs) found on the same pair of genes, in 
consistent order, and overlapping less than 5% (with bit scores penalized proportional to 
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the amount of overlap, computed as the larger of overlap_fraction * HSP_score / 
HSP_length for the two HSPs). Orthologous sets of genes were determined at each tree 
node in two steps. First, if a set or gene from one child of the node was in a mutual best 
hit-relation with a set or gene from the other child, they were combined into a new set. 
Second, following this initial merge step, all hits within the node’s subtree and between 
the subtree and all outgroup genes were considered in descending order of bit score (in 
either source-target gene direction). A better hit to an outgroup gene blocked any further 
merging of a gene or set (until another tree node was visited), while a hit between two 
sets or genes within the subtree, neither previously blocked, resulted in these being 
merged into a new set. This orthology computation was based on that described and 
implemented for the genome sequence of Nematostella (Putnam et al. 2007) with further 
refinement of the blocking rules. Merging of species tree nodes (and of the underlying 
sets of orthologous genes, where in a mutual-best-hit or unblocked-hit relationship) 
continues iteratively until the root node of the species tree is reached. 
The resulting clusters represent families of orthologous genes, and the distribution 
of genes within a cluster provides a picture of the presence/absence of a gene family 
within the representative set of animals (and their closest outgroups). I used the subset of 
clusters containing human OMIM genes for further phylostratigraphic analysis. The 
phylostratification produced by this method is more conservative than that of an 
unbiased, complete BLAST database query to identify gene orthologs by similarity 
threshold, such as the methods used in previous phylostratigraphic studies (Domazet-
Loso & Tautz 2008), because the method adheres to a discrete phylogenetic hierarchy, 
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uses a scoring metric that takes the length of sequence matches into account, and is 
duplication-aware to the extent of distinguishing orthologs and out-paralogs (in-paralogs 
would be interpreted as two distinct ancestral genes at any particular tree node, but can 
become in-paralogous during subsequent merges of parental tree nodes). Therefore, it 
aims to increase specificity at the cost of sensitivity and provides higher-confidence 
orthologous gene relationships than those based simply on sequence similarity below a 
given threshold. This method inherently employs a Dollo-type parsimony model of gene 
evolution by assuming that gene families evolved (or duplicated) once in a single 
common ancestor. In order to qualitatively assess and contextualize the clusters from my 
analysis, I compared the clustering results of a few gene families with known human 
disease gene members to their previously reported phylogenetic relationships. My results, 
which are in agreement with these previously reported phylogenetic relationships, show 
that the clusters are able to detect a wide range of phylogenetically meaningful 
relationships (see section Qualitative Analysis of Clusters). 
Evaluation of Evolutionary Selection Rates of Disease Gene Classes 
I downloaded dN and dS evolutionary rates for all human RefSeq genes from 
BioMart, which are pre-computed for mammalian orthologs in the EnsemblCompara 
GeneTrees (Vilella et al. 2009); dS values become saturated over larger evolutionary 
distances, restricting the species we considered to a subset of eutherian mammals. I 
assigned dN, dS, and dN/dS values to each human gene ortholog from each of the nine 
mammalian species considered, selecting only the top ortholog based on orthology 
confidence, sequence identity, and minimum dN/dS ratio (in order). Of 19170 human 
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genes considered, between 85.0% (rabbit) and 91.8% (chimpanzee) were assigned dN 
and dS values. Of the 2727 disease genes used in the phylostratigraphic analysis, between 
91.6% (rabbit) and 98.3% (mouse) were assigned, and within disease class subsets, 
between 88.1% and 100% were assigned, with a median value of 96.3%. 
To determine whether disease genes from any particular phylostratum had unique 
relative rates of selection (Figure 1.8), I compared the dN/dS rate distributions of genes 
from each phylostratum, restricted to the superset of all human disease genes with dN/dS 
ratios identified in every selected mammalian species (2103 out of 2727 genes). Within 
each mammalian species, dN/dS rate distributions were compared between all pairs of 
phylostrata (Mann-Whitney U two-tailed test; p < 0.05, Bonferroni-corrected). Only the 
vertebrate-specific set shows any significant difference in dN/dS distribution compared to 
the gene sets in other phylostrata, and this difference is significant in every comparison 
except for, within chimpanzee, vertebrate-specific genes versus genes in the Parahoxozoa 
and Bilateria phylostrata, respectively. 
Reproducibility of Disease Gene Phylostratification using Reciprocal-Best BLASTP 
Searches 
In order to assess the robustness of the phylostratification produced by the clusters 
and the reproducibility of the resulting evolutionary signatures of disease classes 
presented in Figures 1.5 and 1.6, I performed a second phylostratigraphic analysis using 
an alternative method. In this case, all OMIM genes with an NCBI RefSeq protein 
counterpart (2874 total, including all 2727 from the ortholog clusters) were queried 
against predicted protein sets of each species independently with a reciprocal BLASTP 
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search. Thus, a given OMIM gene was identified as a reciprocal best BLASTP hit (RBH) 
to a non-human gene within a given species if the OMIM gene and candidate non-human 
gene were both best BLASTP hits to the other, having E-values of less than 1 x 10-3 in 
both cases. Thus, the RBH relationships between human genes and the genes of a non-
human species are one-to-one and consider only OMIM genes, opposed to the 
relationships defined by the ortholog clusters that are many-to-many and include all 
human genes. The RBH method is, therefore, even more specific than the ortholog 
clustering method, but also less sensitive, and should not be expected to produce an 
identical phylostratification. Nonetheless, I use this method to demonstrate that the 
results of my analysis are reproducible and not dependent upon the phylostratigraphic 
method. 
I identified the overlap between the two methods and found that 23,374 OMIM 
gene orthologs were also identified as RBHs (excluding D. pulex, C. intestinalis, and X. 
tropicalis due to problems arising from differences in protein sequence identifiers; see 
Figure 1.3 “Overlap” data). This represents 70.2% of all OMIM orthologs identified and 
78.1% of all OMIM RBHs identified. Overall, I found the two methods to be in relatively 
strong agreement despite their stated differences, but this highlights the fact that 
identifying homologs of human genes from diverse animal species is not an exact 
science. In particular, it is confounded by the abundance of gene families that arose via 
duplication(s) of a common ancestor and the interpretation as to which evolutionary event 
(i.e., the emergence of the founder gene, its duplication, or some other intermediate 
event) is the most relevant. The most robust method would require running phylogenetic 
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trees on each OMIM gene, which is not currently a tractable approach on a large, 
multiple gene family scale because each tree is sensitive to the selection of a suitable set 
of gene sequences (including outgroups) and must be interpreted manually. Other 
methods have considered treating emergence and most-recent duplication events 
independently (Dickerson & Robertson 2012; Vilella et al. 2009), but this complicates the 
ability to study evolutionary distributions of large sets of genes and has not yet been 
applied to newly sequenced genomes. 
In addition to the reproducibility of individual ortholog or RBH assignments for 
OMIM genes, I also evaluated the reproducibility of the phylostratification (i.e., the 
identification of the most distant ortholog) produced by each method and the subsequent 
selection of significantly deviating disease processes. These results are presented in Table 
1.2. I found that 1696 of the 2727 OMIM genes that were considered in both methods 
were placed in the same phylostratum, representing 62.2% reproducibility. When 
allowing for an assignment error to an immediately adjacent bin (e.g., a gene identified as 
first appearing in the Metazoa by one method, but in either the Parahoxozoa or Filozoa in 
the other), the reproducibility increases to 2173 (79.7%); thus, nearly half of the 
inconsistencies between binning methods are still close in relative evolutionary distance. 
Another main source of discrepancy lies in the fact that the ortholog clustering method 
tends to produce a more ancient skew relative to the RBH method, likely because RBHs 
are more stringent in their similarity metric and more prone to false negatives stemming 
from distantly diverging sequence. Thus, an ortholog is identified in the Filozoa for 52% 
of the OMIM genes, whereas only 46.2% have a RBH. 
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Despite the noted differences in the phylostratigraphic methods, however, the 
selection of disease annotations that significantly differ from the null (“All OMIM”) 
model is highly reproducible across methods. Figure 1.5 identifies 29 significantly 
skewed disease distributions, with 27 of these significantly skewed using the RBH 
method as well. Therefore, the ortholog method identifies only two annotations not 
reproduced by the RBH method and, likewise, the RBH method identifies 11 uniquely. 
These unique results generally have less dramatic deviation from the null distribution 
than those that are reproduced. When comparing the distributions for reproduced 
annotations, the overall distributions are expectedly not identical. However, the most 
statistically significant over- and under-representations are well maintained between the 
two methods. I notice a number of annotations that interchange between the multi-stage 
metazoan group (Figure 1.6C) and either the vertebrate-specific (Figure 1.6A) or early 
metazoan (Figure 1.6B) group between phylostratigraphic methods, but no cases exist 
where a disease annotation was placed in the vertebrate-specific group by one method 
and the early metazoan group by the other. Therefore, some of the marginal over-
representations identified in one method may not be identified as significant in the other, 
but I found no cases of major disagreement. Finally, I compared the distributions for each 
annotation (both non-deviating and significantly deviating) across phylostratigraphic 
methods and found that while the two distributions for each matching annotation are not 
identical, they are more similar than expected based on all pairs of across-method 
distribution comparisons (calculated using χ2 two-sample test statistics adjusted for equal 
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degrees of freedom, one-tailed t-test of means where N=76 and 5927 defined 
comparisons, p = 0.0086). !  
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Filozoa Metazoa Parahoxozoa Bilateria Deuterostomia Vertebrata TOTAL 
Filozoa 1074 145 55 51 12 82 1419 
Metazoa 96 183 77 45 6 34 441 
Parahoxozoa 28 37 82 24 10 19 200 
Bilateria 15 12 15 85 10 8 145 
Deuterostomia 12 15 15 18 24 36 120 
Vertebrata 37 27 26 45 19 248 402 
TOTAL 1262 419 270 268 81 427 2727 
Table 1.2. Number of genes binned in each phylostratum by ortholog clusters and RBHs. 
 
Estimation of Sampling Errors from Choice of Taxa 
The evolutionary distributions I have compared are dependent upon the sample of 
species used and their grouping into phylostrata. My analysis is limited by the few 
species with whole-genome sequence available in distant animal lineages. While the goal 
of my analysis was not to identify founder genes, I nonetheless estimated what 
percentage of genes have origins much deeper than the Filozoa, and more specifically, 
how many of those were considered in my analysis to be Metazoa-specific. For example, 
if a disease gene has more ancient origin than the species I have studied but was lost in 
both M. brevicollis and C. owcarzaki, then I cannot conclude whether a gene binned in 
the Metazoa in fact has Metazoa-specific origins, or if it was simply lost in the Filozoan 
species I included. To estimate the occurrence of these events, I performed an 
independent RBH comparison of the human disease gene (OMIM) set versus the genome 
of the yeast S. cerevisiae, yielding a set of 676 genes out of 2874 (23.5%; see Figure 1.3). 
This was used as a representative set of genes that could be considered to have pre-
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metazoan origins with relatively high confidence. I then compared the phylostratification 
of this gene set by each phylostratigraphic method to see how often these yeast genes 
were placed in the most basal phylostratum (Filozoa), indicating likely pre-metazoan 
origins. 
For the ortholog clustering method, 655 of the 676 yeast homologs were included 
in the clusters. 572 of these were binned in the Filozoa, suggesting the other 83 are found 
only in the metazoan genomes, indicating potential loss in the filozoans I studied. This 
represents about 3% of the 2727 clustered genes: 51 were instead binned in the Metazoa, 
eight in the Parahoxozoa, five in the Bilateria, four in the Deuterostomia, and 15 in the 
Vertebrata. For the RBH method of phylostratification, 47 of the 676 yeast homologs 
were not binned in the Filozoa, representing about 1.6% of the 2874 genes with RBHs. 25 
of these were instead binned in the Metazoa, 12 in the Parahoxozoa, four in the Bilateria, 
one in the Deuterostomia, and five in the Vertebrata. These data suggest that despite not 
looking beyond the Filozoa, very few genes with likely pre-metazoan origins were 
considered Metazoa-specific in the analyses. 
Qualitative Analysis of Clusters 
In order to qualitatively assess the orthologous gene clusters of human disease 
genes, I compared the clusters to well-studied human disease genes that are members of 
multi-gene families with known phylogenetic relationships. Specifically, I considered 
gene families whose evolutionary origins have been studied with extensive phylogenetic 
analyses, including gene family-specific phylogenetic trees that include an evolutionarily 
appropriate set of species and gene candidates. In practice, these are the types of in-depth, 
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gene family-specific analyses that should be done on a human disease gene of interest 
prior to selecting a specific model organism. Thus, I present this analysis as a proof-of-
concept in regard to the validity of the clusters and their improvement over one-
directional BLAST searches, while demonstrating the contextual aspects that need to be 
further considered for individual disease genes. !  
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Figure 1.9. Clusters of human disease genes from known multi-gene families. 
(A) Apolipoproteins, (B) Caspase enzymes, and (C) components of the TGF-β signaling pathway. !  
!!
53 
Apolipoproteins 
Figure 1.9A shows a set of apolipoprotein human disease genes and their 
corresponding orthologous gene clusters. The APOB gene and the other APO genes are 
distinct from one another; APOB apolipoproteins form low-density lipoprotein whereas 
the others form high-density lipoprotein. Furthermore, APOB has been shown to share a 
common ancestor with the Vtg gene, which appears to have arisen ~700 million years 
ago in the early Parahoxozoa (Hayward et al. 2010; Babin & Gibbons 2009), consistent 
with Cluster A5. I note that Cluster A5 does not contain an ortholog in T. adhaerens (but 
does contain a RBH to APOB), likely due to the difference in domain structures between 
the Vtg ortholog identified in T. adhaerens and the rest of the gene family, including N. 
vectensis orthologs (Hayward et al. 2010). Thus Cluster A5 is consistent with the 
reported phylogenetic gene tree for APOB and Vtg (Hayward et al. 2010) by grouping 
the orthologs in N. vectensis and D. melanogaster with the human APOB, but excluding 
the genes that are more Vtg-like in T. adhaerens and C. elegans. 
However, the other apolipoprotein genes arose from an unrelated evolutionary 
event, likely pre-dating tetrapods and teleosts in the earliest vertebrates (Babin et al. 
1997; Babin & Gibbons 2009). This appears to have represented the ancestral form of the 
human APOA, APOC, and APOE genes (and possibly others). However, subsequent 
local or full gene duplications have diversified the gene family, with the APOE, APOA1, 
and APOA5 human disease genes (and the non-disease gene APOA4; data not shown) all 
having at least six more duplications of 11 or 22 codons than the APOA2 and APOC 
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genes (W.-H. Li et al. 1988; Boguski et al. 1986). This evolutionary history corresponds 
logically with Clusters A1-A4. 
Caspases 
Caspase (cysteinyl aspartate proteinase) enzymes have multiple roles in metazoan 
programmed cell death (apoptosis) and inflammation, which are central to many human 
diseases. Specifically, CASP8, CASP10 and CASP12 were amongst my OMIM set of 
human disease genes, and I show their corresponding clusters in Figure 1.9B. These three 
caspases group in two clusters; CASP12 forms Cluster B1 with five other human non-
disease genes (including CASP1, CASP4, CASP5, CARD16 and CARD17; data not 
shown), while CASP8 and CASP10 form Cluster B2. These relationships are consistent 
with previous phylogenetic analyses of caspases, where CASP8 and CASP10 form their 
own subfamily of initiator caspases with a death effector domain (DED) in place of the 
caspase recruitment domain (CARD) (S. R. Dunn et al. 2006; Lamkanfi 2002; Taylor et 
al. 2008); an ortholog to this subfamily has previously been identified in the sponge A. 
queenslandica, but not outside of the Metazoa (Srivastava et al. 2010). Furthermore, the 
absence of an ortholog (but presence of an RBH) in D. melanogaster and C. elegans is 
expected, as those species have similar, but lineage-specific caspases (e.g. DREDD, 
DECAY, DRICE, and DRONC) (Lamkanfi 2002; S. R. Dunn et al. 2006). CASP12, on 
the other hand, is an inflammatory caspase more closely related to CASP1, CASP4, 
CASP5, and CASP11 than to CASP8 and CASP10 (Taylor et al. 2008; Lamkanfi et al. 
2003). 
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TGF-β pathway components 
Transforming growth factor β (TGF-β) signaling is an important developmental 
pathway found only in metazoans (Richards & Degnan 2009; Pang et al. 2011; Detournay 
et al. 2012). In the disease gene set, I find multiple components of the pathway, including 
multiple ligands, receptors, and intracellular SMAD proteins. Within the ligands, I find 
disease genes from both the TGF-β-like and BMP-like groups, including TGFB1-3, 
Myostatin, LEFTY2, BMP2/4, and GDF3 (Figure 1.9C). The TGF-β-like ligands form 
Clusters C1-C3, whereas all of the BMP-like ligands cluster together in Cluster C4. 
Cluster C1 represents the TGF-β sensu stricto ligands (TGFB1-3). These ligands 
were originally thought to exist only in vertebrates, but the identification of homologs in 
A. queenslandica and M. leidyi, as well as similar ligands in other species, suggested they 
emerged at the base of the Metazoa (Detournay et al. 2012; Richards & Degnan 2009; 
Pang et al. 2011). In this cluster, orthologs are found in all Deuterostomes and also the 
poriferan A. queenslancia. This demonstrates the ability of the orthologous gene-
clustering algorithm to identify distant orthologs in cases where many species, from the 
Parahoxozoa up until Deuterostomia, have lost the underlying gene. However, the 
clusters only identify the A. queenslandica ortholog and not the M. leidyi ortholog, 
demonstrating that largely diverged sequences are harder to classify. It has been 
previously demonstrated that the M. leidyi TGF-β sensu stricto ligand is the least 
homologous member of the ligand family (Detournay et al. 2012; Pang et al. 2011). I note 
that although the A. queenslandica ortholog is most similar to the TGFB3 human 
counterpart (based on the RBH results), the clustering suggests that the ancestral form 
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duplicated in the Deuterostomes to form the larger class of three TGF-β sensu stricto 
ligands seen in humans. 
Cluster C2 contains the human disease gene myostatin (MSTN) as well as five 
other human non-disease genes representing inhibins (INHBA/B/C/E) and GDF11 (data 
not shown). Cluster C3 contains the human disease gene LEFTY2 as well as LEFTY1, a 
non-disease gene (data not shown). Taken together, the grouping of Clusters C1-C3 is 
meaningful from both a sequence-similarity perspective as well as a phylogenetic origins 
perspective. While these various classes of TGF-β are all distinct, they likely have a 
common ancestor dating back to the earliest metazoans. However, the Lefty ligands have 
been found only in Deuterostomes (Cluster C3 identifies a possible ortholog in C. teleta 
as well), whereas the TGF-β sensu stricto and myostatin, activin and inhibin ligands arose 
from more ancient duplications (Pang et al. 2011; Detournay et al. 2012). Furthermore, 
the representatives from the myostatin cluster are found in more protostome and non-
bilaterian lineages than the TGF-β sensu stricto ligands. Thus, each cluster represents a 
set of TGF-β-like ligands that exhibit both sequence similarity and distinct evolutionary 
origins. 
The other class of TGF-β ligands is the BMP-like ligands, represented by the 
human disease genes in Cluster C4. In each of the non-Deuterostome species studied 
here, Cluster C4 contains at most one ortholog to the full set of human BMP-like ligand 
disease genes. Generally, that ortholog is an RBH to BMP2, but not always. This is a case 
where duplications in the earliest Deuterostomes are not determined by the clustering to 
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create a new, unique subfamily of paralogous genes, and using RBH relationships alone 
would not reveal this level of detail regarding gene family evolution. 
The TGF-β receptor genes are generally classified as type I or type II; the human 
disease gene set includes only the type II receptors in Cluster C5. This cluster also 
contains the human non-disease gene ACVR2A (data not shown). I note that a TGF-β 
type II receptor was previously identified in M. leidyi (Pang et al. 2011), but was an 
outgroup to the rest of the gene family, explaining why it was likely excluded from this 
cluster. 
Lastly, the SMAD proteins are important to the TGF-β signaling pathway. The 
human disease gene set contains five SMAD genes that are grouped into three 
meaningful clusters. The inhibitory I-SMADs (SMAD6 and SMAD7) form Clusters C6 
and C7, whereas the receptor-associated SMADs (R-SMADs) and common-mediator 
SMADs (Co-SMADs) group in Cluster C8. This clustering is logical because the non-
inhibitory R-SMADs and Co-SMADs have multiple orthologs in the earliest metazoans 
(Pang et al. 2011), suggesting the entire class is defined by its early origins opposed to 
more recent duplications and/or divergence. In addition to the human disease genes 
shown, Cluster C8 also contains other non-disease-associated SMADs: SMAD2, 
SMAD5, and SMAD9 (data not shown). On the other hand, the inhibitory I-SMADs in 
Clusters C6 and C7 are similar to each other (and distinct from the R/Co-SMADs), but 
have different evolutionary origins. SMAD6 has distant orthologs in many protostomes 
and non-bilaterian metazoans (Pang et al. 2011), but SMAD7 appears to be a paralog of 
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SMAD6 that arose from a duplication in the early vertebrates. In this case, the clusters 
separate the two into distinct, meaningful classes of I-SMADs. 
Finally, I highlight one potential drawback of the clusters based on Cluster C8. 
An ortholog is identified in both of the non-metazoans C. owczarzaki and M. brevicollis, 
although these species are not known to have any SMAD proteins (Pang et al. 2011). 
Upon further inspection, this cluster includes the A. queenslandica predicted protein 
Aqu1.225807, which appears to be a SMAD protein merged with a Translin protein. This 
likely represents an incorrectly predicted protein model fusing two separate genes, or 
alternatively, a novel protein not seen in any other species. As a result, the Translin 
family of proteins was grouped with the SMAD proteins in this cluster, resulting in 
orthologs being identified in these non-metazoans to the human Translin gene (data not 
shown). Thus, using a combined sequence similarity and phylogenetic tree-based 
clustering method is inherently sensitive to cases where a single inaccurately predicted 
protein can affect the entire family classification. Fortunately, these situations are 
uncommon, but nonetheless demonstrate the importance of using high-quality sequence 
data from well-annotated genome projects. It also highlights the utility of considering the 
RBH results as complementary to the clusters, because the non-metazoan Translin 
orthologs are not RBHs to the SMAD proteins in the human disease gene set. 
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CHAPTER 2. MICRORNAS AND ESSENTIAL COMPONENTS OF THE 
MICRORNA PROCESSING MACHINERY ARE NOT ENCODED IN THE 
GENOME OF THE CTENOPHORE MNEMIOPSIS LEIDYI 
Background 
MicroRNAs (miRNAs) are a class of small RNA molecules derived from 
transcribed mRNA hairpin structures and spliced introns (Ruby et al. 2007; Berezikov et 
al. 2007; Axtell et al. 2011) that play a key role in mRNA targeting, leading to the 
degradation or translational repression of the target transcript. The regulatory functions of 
miRNAs are essential to many key biological processes in metazoans, including 
development, cell growth and death, stem cell maintenance, hematopoiesis, and 
neurogenesis. Aberrations in miRNA regulation have been linked to blood disorders, 
oncogenesis, and other malignancies in humans (Schickel et al. 2008). The hairpin 
structures in mRNA transcripts that give rise to primary microRNAs (pri-miRNAs) are 
not unique to miRNAs or metazoans; these hairpins can form much more frequently than 
functional pri-miRNAs (Axtell et al. 2011; N. Liu et al. 2008) and can arise from inverted 
duplications, transposable elements, and genomic repeats (Axtell et al. 2011; Berezikov 
2011; Shabalina & Koonin 2008). Metazoans, however, possess a unique complement of 
cellular machinery for processing and transporting mature miRNAs to their targets that 
has not been identified in any non-metazoan species to date (Kosik 2009; Grimson et al. 
2008; Cerutti & Casas-Mollano 2006; Kim et al. 2009). It has been observed that once 
novel miRNAs emerge in a metazoan lineage, they are very rarely lost. Thus, miRNAs 
are thought to represent strong phylogenetic markers and, through their ability to fine-
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tune gene expression, appear to be major drivers of biological complexity (Kosik 2009; 
Peterson et al. 2009; Wheeler et al. 2009; Niwa & Slack 2007).  
The canonical miRNA biogenesis pathway in metazoans is part of the larger RNA 
interference (RNAi) pathway, which includes the closely related siRNA pathway (Figure 
2.1). The miRNA pathway is distinct from the ancestral siRNA pathway in that it is 
initiated by the cleavage of hairpin structures (i.e., pri-miRNAs) from mRNAs in the 
nucleus by the Drosha/Pasha complex (also known as the Microprocessor complex), 
producing precursor-miRNAs (i.e., pre-miRNAs) that can be exported into the cytosol via 
the Exportin-5—Ran-GTP complex. After being transported into the cytosol, miRNAs 
and siRNAs undergo the same processing and targeting steps, initiated by Dicer cleavage 
and loading into the RNA-induced silencing complex (RISC) with Argonaute (Bartel 
2004). The siRNA pathway is an ancient biological defense mechanism used to ward off 
the integration of foreign nucleic acids, such as double stranded RNAs (dsRNAs) 
introduced by viruses, and is known to have existed in the oldest eukaryotes (Shabalina & 
Koonin 2008; Cerutti & Casas-Mollano 2006). Thus, the emergence of the metazoan 
canonical miRNA biogenesis pathway most likely coincided with the evolution of the 
Drosha/Pasha complex found only in metazoans (Cerutti & Casas-Mollano 2006; Kim et 
al. 2009). Functionally, the Drosha/Pasha complex enables cleavage of pri-miRNA 
hairpins that are subsequently exported out of the nucleus and processed by the pre-
existing RNAi pathway. 
Given the differences in molecular machinery, processing, and target recognition, 
miRNAs are thought to have evolved separately and exclusively in animals and plants 
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(Axtell et al. 2011; Shabalina & Koonin 2008; Grimson et al. 2008; Jones-Rhoades et al. 
2006). However, a number of recent studies have reported identification of miRNAs in 
unicellular eukaryotes, including several thought to be homologs of miRNAs specific to 
animal and plant lineages (Hinas et al. 2007; Cock et al. 2010; A. Huang et al. 2011; W.-
C. Lin, Li, et al. 2009b; X. S. Chen et al. 2009b; P.-J. Huang et al. 2012; W.-C. Lin, 
Huang, et al. 2009a; W. Li et al. 2011; Saraiya et al. 2011; Saraiya & C. C. Wang 2008; 
Braun et al. 2010; Molnár et al. 2007; Zhao et al. 2007). These studies imply that 
miRNAs evolved once, early in eukaryotic evolution. Nevertheless, a recent report 
(Tarver et al. 2012) reexamined these studies and found that, of the cumulative 232 
reported miRNAs, none of the putative plant or animal homologs met established criteria 
for miRNA annotation; they were, instead, likely traces of other small RNAs (e.g., 
siRNAs, rRNAs, or snoRNAs) that happened to fit the length spectrum of mature miRNA 
sequences. Additionally, only 28 of the putative novel miRNAs passed the annotation 
criteria, and those were restricted to green and brown algae. In light of this evidence, it 
appears most likely that miRNAs evolved independently in multiple eukaryotic lineages, 
with the metazoan pathway being dependent upon the Drosha/Pasha protein complex. 
Here, I describe an in-depth characterization of both the miRNA biogenesis 
pathway proteins and genomic regions that may correspond to pri-miRNA loci in the 
recently sequenced genome of Mnemiopsis leidyi (J. F. Ryan et al. 2013). Recent 
phylogenomic analyses suggest that Ctenophora is the earliest branching metazoan 
lineage (C. W. Dunn et al. 2008; Hejnol et al. 2009; J. F. Ryan et al. 2013), and genomic 
studies of a number of gene superclasses (J. F. Ryan et al. 2010b; Reitzel et al. 2011) and 
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signaling pathways (Pang et al. 2011) in Mnemiopsis are consistent with this theory. If 
ctenophores are, indeed, the earliest metazoan branch, examining the genome of 
Mnemiopsis provides us a rare opportunity to better understand the origin of miRNA 
processing in metazoans. Alternatively, if ctenophores branched later in evolution and 
Porifera is the most basal metazoan lineage (Pick et al. 2010), Mnemiopsis still provides a 
valuable model from which to study the early evolution of this important small RNA 
processing pathway. Putative miRNAs (and the pathway proteins involved in their 
canonical biogenesis) have been studied in other non-bilaterian metazoans, including 
Nematostella vectensis, Hydra magnipapillata, Trichoplax adhaerens, and Amphimedon 
queenslandica (Grimson et al. 2008; Wheeler et al. 2009; Chapman et al. 2010). The 
complete processing pathway was identified in all cases except Trichoplax, which lacks a 
Pasha homolog and recognizable miRNAs (Berezikov 2011; Grimson et al. 2008; Hertel 
et al. 2009). However, the presence of Drosha, Pasha, and miRNAs in Amphimedon, a 
metazoan lineage that branched prior to Trichoplax, suggests that Trichoplax must have 
lost miRNA functionality (Grimson et al. 2008). 
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Figure 2.1. Metazoan miRNA and siRNA pathways. 
Representation of standard metazoan models for canonical miRNA biogenesis, mirtron biogenesis, and siRNA 
processing. The Drosha/Pasha protein complex is specific to canonical miRNA biogenesis and initiates cleavage of the 
primary miRNA (pri-miRNA) from transcribed mRNAs. Intronic miRNAs (mirtrons) bypass cleavage by 
Drosha/Pasha, generating precursor miRNAs (pre-miRNAs) via intron splicing of mRNAs. The Dicer and Argonaute 
proteins are responsible for further processing and transport of miRNAs, in addition to short-interfering RNAs 
(siRNAs) from exogenous sources, resulting in repression of mRNA targets.  
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Results and Discussion 
In order to understand the increasing complexity observed in the early evolution 
of animals, our lab recently sequenced and annotated the Mnemiopsis genome (J. F. Ryan 
et al. 2013; Moreland et al. 2014). As an estimate of genome completeness, 99.4% of the 
15,752 publicly available Mnemiopsis EST sequences map to the genome assembly. 
Through my examination of the Mnemiopsis genome and its predicted proteome, I was 
able to identify multiple RNAi pathway proteins necessary for miRNA and siRNA 
processing, including Dicer, Argonaute, Ran, and exportin-5, but the miRNA-specific 
biogenesis pathway proteins Drosha and Pasha are strikingly absent. To my knowledge, 
this is the first reported case of a metazoan genome lacking a Drosha homolog. Since 
Dicer and Drosha are both members of the ribonuclease III (RNase III) protein family 
(Figure 2.2), I focused my analysis on the RNase III protein domain to better characterize 
the Mnemiopsis Dicer protein and to yield insight into how, through the evolution of this 
protein family in the Metazoa, the canonical miRNA biogenesis pathway may have 
emerged. 
Drosha and Dicer belong to subclasses 2 (Drosha) and 3 (Dicer) of the RNase III 
protein family (MacRae & Doudna 2007). Both proteins are characterized by tandem 
RNase III domains that cleave dsRNA to a specific length, often producing cleavage 
products with a two-nucleotide 3’ overhang. However, distinct differences have been 
observed in the dsRNA-binding specificity and cellular localization of these two RNase 
III subclasses (MacRae & Doudna 2007). Class 3 RNase III enzymes have a PAZ domain 
that recognizes dsRNA ends with the distinctive two-nucleotide 3’ overhang indicative of 
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prior RNase III cleavage. Class 2 RNase III enzymes do not appear to contain a domain 
with specific affinity for dsRNA and, instead, rely on complex formation in the nucleus 
with a co-factor (Pasha, or DGCR8 in vertebrates) that recognizes the ssRNA-dsRNA 
junctions characteristic of pri-miRNA hairpins (MacRae & Doudna 2007). RNase III 
class 3 Dicer-like proteins that lack a PAZ domain (and have a domain structure more 
similar to Drosha) have been identified in non-metazoans but function as part of an 
unrelated pathway (Mochizuki 2005); they have also been identified in early branching 
metazoans, but their function has not been confirmed experimentally (Mochizuki 2005). 
Since deletion of the PAZ domain in a functional Dicer has been shown to produce an 
RNase III enzyme without target specificity (MacRae et al. 2007), there are likely 
functional binding domains other than PAZ within the RNase III class 3 subfamily. 
To determine which class(es) of RNase III enzymes the Mnemiopsis Dicer protein 
is most closely related to, I performed a phylogenetic analysis on the RNase III domains 
of early-branching metazoan Dicer and Drosha proteins. I used HMMER (Finn et al. 
2011) to search available non-bilaterian animal protein sequences (i.e., Mnemiopsis, 
Nematostella, Hydra, Trichoplax, and Amphimedon) to identify all candidate class 2 or 
class 3 RNase III proteins containing tandem RNase III domains. My search yielded only 
one Dicer protein in Mnemiopsis and numbers of proteins consistent with other reports on 
the early-branching Metazoa (Grimson et al. 2008; D. de Jong et al. 2009). I included a 
sample of bilaterian Dicer and Drosha sequences in my analysis to ensure each protein 
class was monophyletic across the Metazoa. I separated the RNase IIIa and RNase IIIb 
domains of each protein (Figure 2.2), aligned the domains, trimmed the poorly conserved 
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and flanking regions, and used the resulting alignment as the basis for further 
phylogenetic analysis (see Table 1.1 and (Maxwell et al. 2012)). 
The tree generated from this alignment (Figure 2.3A) contains separate clades for 
each RNase III domain subgroup, confirming the characterization of the Mnemiopsis 
RNase III protein as a Dicer protein. Importantly, the topology unites the Drosha RNase 
IIIa and RNase IIIb domains with the respective Dicer RNase III domains. Given that 
RNase III class 2 (Drosha) proteins are restricted to the Metazoa (Cerutti & Casas-
Mollano 2006; Kim et al. 2009), whereas RNase III class 3 (Dicer) proteins are found in 
the RNAi pathways of ancestral eukaryotes (Shabalina & Koonin 2008; Cerutti & Casas-
Mollano 2006; D. de Jong et al. 2009), this topology suggests that Drosha evolved from 
Dicer via a duplication event early in the evolution of the Metazoa, roughly coinciding 
with the emergence of miRNA functionality (Figure 2.3B). This observation contradicts 
the less parsimonious argument that these double RNase III domain-containing enzymes 
evolved independently from separate eubacterial RNase III domains (Cerutti & Casas-
Mollano 2006) (Figure 2.4). 
It is possible that Mnemiopsis utilizes alternative methods for producing miRNAs 
for transcriptional regulation. Therefore, I searched for miRNAs using data from short 
RNA sequencing runs on two Mnemiopsis samples. I was unable to identify any known 
metazoan miRNAs that mapped to the Mnemiopsis genome. While I was able to predict 
several novel miRNA candidates using two methods, no predictions were reproducible 
across all samples and methods. In addition, even the highest-scoring predictions 
exhibited atypical read mapping signatures. Thus, I have classified all of these predictions 
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as false positives, as they do not appear to be processed by the canonical miRNA 
machinery (see Materials and Methods). 
Some spliced introns can correctly fold into pre-miRNAs, called mirtrons, 
independent of cleavage by Drosha and Pasha (Ruby et al. 2007; Berezikov et al. 2007; 
Berezikov 2011) (Figure 2.1). However, within the Mnemiopsis genome, only a handful 
of introns have predicted secondary structures suggestive of mirtron-coding potential, and 
none of these have read mapping signatures to indicate that they are functional mirtrons. 
The presence of exportin-5 and downstream RNAi pathway proteins Dicer and 
Argonaute in Mnemiopsis could indicate the existence of an alternative mechanism for 
miRNA production that predates the canonical miRNA pathway. The lack of 
recognizable miRNAs in the small RNA sequences, however, suggests that this scenario 
is unlikely. Recently, cases of functional exogenous miRNAs acquired via ingestion were 
identified in animals (Lin Zhang et al. 2012), suggesting a possible dietary mechanism by 
which Mnemiopsis could utilize miRNA regulatory functions in the absence of a 
functional endogenous canonical pathway. However, the mechanism for exogenous 
miRNA activity remains poorly understood. 
It has been hypothesized that mirtrons may have predated the Drosha/Pasha-
mediated pathway, based on the observation that the mechanistic requirements for their 
evolution may have been fairly simple (Ruby et al. 2007; Berezikov et al. 2007). The 
identification of mirtrons in rice (Axtell et al. 2011; Flynt et al. 2010) and the presence of 
the necessary machinery in Mnemiopsis (described above) are consistent with this 
hypothesis. However, given the absence of functional mirtrons in Mnemiopsis, it appears 
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more likely that miRNA functionality evolved alongside the Drosha/Pasha-mediated 
pathway, independently of the mirtron pathway. Discerning the point in evolutionary 
time in which mirtrons became functional will require a thorough analysis of the 
genomes of additional species beyond nematodes, mammals, and avians (Axtell et al. 
2011; Flynt et al. 2010). 
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Figure 2.2. Typical domain architectures of Ribonuclease III and Pasha proteins. 
Members of the Ribonuclease III (RNase III) protein family all contain RNase III protein domains responsible for 
binding Mg2+ ions that cleave individual strands of dsRNA. The dsRNA binding domain (dsRBD) is common to most 
RNase III proteins and Pasha. Other common domains found in RNase III class 3 (Dicer) proteins include PAZ, a 
domain of unknown function (DUF), and a helicase. Pasha contains only tandem dsRBD domains, a domain 
architecture relatively common in other dsRNA binding proteins within metazoan proteomes. 
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Figure 2.3. Evolution of metazoan RNase III domains. 
(a) Cladogram of isolated RNase III domains from metazoan Dicer and Drosha proteins. Mnemiopsis Dicer protein 
RNase III domains are labeled in red. Bootstrap support values above 45, based on 1000 bootstrap replicates, are 
displayed on branches with Bayesian probabilities as indicated. See Table 1.1 for information on sequence identifiers. 
(b) Scenario for Drosha evolution. Dicer proteins evolved from a duplicated RNase III domain early in eukaryotic 
evolution. Drosha proteins evolved from a duplicated Dicer protein early in metazoan evolution. White ‘a’ and ‘b’ 
labels represent RNase IIIa and RNase IIIb domains of Dicer and Drosha proteins, respectively. Green, yellow, pink 
and blue domains correspond with the clades shown in (a).  
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Figure 2.4. Evolution of metazoan and eubacterial RNase III domains. 
(a) Phylogenetic tree of isolated RNaseIII domains from metazoan Dicer (green and yellow) and Drosha (pink and 
blue) proteins and eubacterial RNaseIII class 1 enzymes (brown). The RNaseIIIa and RNaseIIIb domains from the 
Mnemiopsis Dicer protein are highlighted in red. Support for branches is based on 1000 bootstrap replicates and 
Bayesian posterior probabilities computed with Mr. Bayes. The displayed tree was generated by the same steps as 
Figure 2.3 and shows the maximum likelihood tree based on 49 trees; 24 with RAxML based on random starting trees, 
24 with RAxML based on 24 maximum parsimony starting trees, and one bayesian tree from Mr. Bayes. The maximum 
likelihood tree (log likelihood = −6838.149995) shown was computed by RAxML using a random starting tree. See 
Table 1.1 for information on sequence identifiers. (b) Indicates the most parsimonious scenario for Drosha evolution as 
described in Figure 2.3, with the addition of eubacterial RNaseIII proteins. This scenario supports independent 
evolution of the Dicer and Drosha sequences from eubacterial RNaseIIIs. The RNaseIIIa and RNaseIIIb domains of 
Dicer and Drosha proteins are indicated with the respective a and b labels in white. Domain colors correspond to clades 
in (a).  
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Table 1.1. RNaseIII domain sequence identifiers and sources.  
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Conclusions 
The implications of these results depend upon the phylogenetic position of 
Ctenophora. If ctenophores are the most basal metazoan clade, the most parsimonious 
explanation for my observations is that metazoan miRNA functionality originated after 
ctenophores diverged from the rest of animals (Figure 2.5A). Alternatively, if poriferans 
are the most basal metazoan clade, then Drosha, Pasha and canonical miRNA 
functionality must have been lost in the Mnemiopsis lineage (Figure 2.5B). If the latter 
were true, then canonical microRNAs and their machinery would have been 
independently lost in both Ctenophora and Placozoa. Recently, genome and 
transcriptome sequencing of a second ctenophore species (Pleurbrachia bachei) has 
further corroborated my findings; this newly sequenced ctenophore species also lacks 
canonical miRNAs (Moroz et al. 2014). Furthermore, phylogenetic analyses of both the 
M. leidyi and P. bachei genomes suggest that Ctenophora is the sister group to all other 
extant animal phyla (Figure 2.A) (Moroz et al. 2014). This, along with the large-scale 
losses of miRNAs described in acoelomorphs (Philippe et al. 2011) and cnidarians 
(Chapman et al. 2010), would contradict the premise that miRNAs are ultraconserved, 
canalized characters that are continuously added, but rarely lost. These data challenge the 
usefulness of miRNAs as phylogenetic markers (Peterson et al. 2009; Wheeler et al. 
2009), and the latest analysis of miRNA-based phylogenetic inference methods further 
contradicts their validity (Thomson et al. 2014). 
My data supports a scenario in which the role of miRNAs in fine-tuning gene 
expression was not solidified until more recently in metazoan evolution and thus 
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indicates that miRNA regulatory functions were, perhaps, non-essential during early 
metazoan diversification. Given this, the lack of recognizable miRNA functionality in 
Mnemiopsis supports a scenario with Ctenophora branching at the base of the Metazoa, 
prior to the emergence of miRNA functionality (Figure 2.5A). It may also indicate that a 
novel RNA-based regulatory pathway evolved either within the ctenophore lineage or as 
a precursor to the canonical miRNA pathway recognizable in the rest of the Metazoa. In 
either case, ctenophores represent an intriguing model for better understanding the early 
evolution of small RNA-based regulatory functions, shedding light on a point in 
evolutionary time that may have predated the need for additional plasticity in key 
molecular systems inherent to animals. I expect that further exploration of the genomes of 
other ctenophores, early branching metazoans, and closely related non-metazoans will 
help determine the exact point in evolutionary history at which both canonical and 
mirtron-based miRNA pathways (and their components) emerged. !!  
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Figure 2.5. Scenarios of the evolutionary implications of canonical miRNA functionality absence in Mnemiopsis 
leidyi.   
(a) Ctenophora (represented by M. leidyi) branching earlier than Porifera (represented by A. queenslandica). In this 
scenario, miRNA functionality likely emerged after the branching of Ctenophora. (b) Porifera branching prior to 
Ctenophora. In this scenario, miRNA functionality coevolved with the Metazoa and was lost from Mnemiopsis leidyi, 
along with the biogenesis proteins Drosha and Pasha. Also shown are the closest outgroups to the Metazoa with 
sequenced genomes (i.e., S. arctica, C. owczarzaki, S. rosetta, and M. brevicollis); see Materials and Methods for 
details on the identification of miRNA pathway proteins in these species. !  
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Materials and Methods 
Sequencing of Short RNAs and Genome Mapping 
For the basis of my analysis, I used small RNA sequencing data from two 
Mnemiopsis embryo samples (Sample 1 originated from Woods Hole, MA, Sample 2 
originated from Miami, FL). These samples were sequenced on the Illumina GAIIx 
sequencer, and deposited in the NCBI Short Read Archive 
(http://www.ncbi.nlm.nih.gov/sra/), accession SRA057204 (see (Maxwell et al. 2012) for 
more detail). 
Using this sequence data, the 3’ adapter sequence 
ATCTCGTATGCCGTCTTCTGCTTGT was trimmed from reads using Novocraft’s 
Novoalign v2.07.18. After filtering reads of low quality, I mapped the trimmed reads to 
the Mnemiopsis genome (J. F. Ryan et al. 2013; Moreland et al. 2014) independently with 
both Novoalign and Bowtie v0.12 (Langmead et al. 2009) (allowing up to two 
mismatches). Novoalign successfully mapped 65.9% of reads from sample 1 (out of 
14,965,804 reads after removal of an overrepresented, unannotated rRNA transcript) and 
58.5% of reads from sample 2 to the genome (out of 30,311,098 reads). Bowtie mapped 
68.3% and 66.7% of reads from each sample, respectively. Rough estimates showed that 
~94% of read mappings from sample 1 were represented in sample 2 and, conversely, 
~91% of read mappings from sample 2 were represented in sample 1. This indicates that 
differences in samples and sequencing protocols did not significantly affect read sources.  
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Canonical miRNA Prediction 
miRDeep2 (Friedländer et al. 2012) and miRanalyzer (version 0.2) (Hackenberg 
et al. 2009) were used to predict miRNAs from the short RNA sequence data and the 
Mnemiopsis genome. Candidate predictions were restricted to those present in both 
samples in at least one read. Next, candidate miRNAs were ranked by the number of 
methods predicting them, where identification in both methods was considered most 
confident and predictions by miRDeep2-only were favored over miRanalyzer-only. This 
ranking is a result of noise filtering to reduce false positives in miRDeep2, producing 
fewer predictions (143 in sample 1 and 248 in sample 2 with miRDeep2, versus 4197 in 
sample 1 and 9056 in sample 2 with miRanalyzer). 
For miRDeep2, I used all metazoan mature miRNA sequences in miRBase 
(Griffiths-Jones et al. 2006) as the input set of known miRNAs. This is used to identify 
potentially conserved miRNAs, in addition to providing a template for estimating the 
false positive rate and signal-to-noise ratio at different score cutoffs (Friedländer et al. 
2012). No known metazoan miRNAs, including those of other early branching metazoans 
studied in this work, were identified in the Mnemiopsis samples based on strict sequence 
similarity having identical seed sequences (nucleotides 2-7) and a maximum of three 
mismatches in the remaining mature or mature-star arm (Wheeler et al. 2009). The 
reported signal-to-noise distributions for each sample were notably dissimilar to those 
reported in other species with known miRNAs (Friedländer et al. 2012). The signal-to-
noise ratio is expected to be roughly monotonically increasing with respect to miRDeep2 
scores and, in other species including Nematostella, should provide a true positive score 
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cutoff at which signal-to-noise is 10:1, or in the worst case (sea squirt), at least 3.5:1. In 
the Mnemiopsis samples, the signal-to-noise ratio peaks at 1.6:1 and 1.3:1, respectively at 
a score cutoff of 4, and drops off at higher scores. Although in those experiments the 
input set of known miRNAs was specific to a single species, opposed to all metazoans, 
the distributions of signal-to-noise ratio versus score cutoffs does not appear high enough 
to make any positive predictions in my experiments. Further, the top Mnemiopsis 
predictions were sample-specific. 
For miRanalyzer, I used all Rfam sequences, provided automatically by the 
program, to identify known miRNAs and to filter short RNA sequences from other 
sources. In both samples, no known miRNA mature or mature-star sequences were 
identified. I did not use miRanalyzer predictions alone to identify novel miRNAs because 
of the immense number of predictions made. Manual analysis showed that the most 
highly expressed predictions corresponded to rRNA sequences. I therefore only used 
miRanalyzer predictions to support miRDeep2 predictions. 
The best predictions over all samples and methods were made by miRDeep2 on 
sample 2. Thus, in addition to looking at the top predictions using the combinatorial 
criteria described above, I also looked at miRDeep2 predictions for each sample 
independently. No predicted miRNA had the ideal combination of read mapping 
signature and secondary structure to be considered a confident miRNA (raw and 
formatted predictions can be found in (Maxwell et al. 2012)). 
Finally, in the absence of confident miRNA predictions by the methods described 
above, I searched the Mnemiopsis genome specifically for miR-100 and miR-2022, as 
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these miRNAs are the only known miRNAs (to my knowledge) thought to be conserved 
outside of the Bilateria; miR-100 appears to be conserved between Nematostella and 
bilaterians, while miR-2022 appears to be conserved between Nematostella and Hydra. 
Querying the Mnemiopsis genome with BLASTN using the conserved portions of the 
respective mature sequences (miR-100: ACCCGTAGATCCGAACTTGTG, miR-2022: 
TTTGCTAGTTGCTTTTGTCCC) yielded partial hits in both cases (14 and 16-
nucleotide identity, respectively). However, only one hit (for miR-2022 on scaffold 
ML1502) covered the expected seed site, and no short RNA sequencing reads from either 
sample mapped to this region. In all, these results support the absence of miR-100 and 
miR-2022 in Mnemiopsis in addition to all other canonical miRNAs.  
Mirtron Prediction 
The basis of the mirtron prediction method was the combination of an absolute 
count of mapping reads from Bowtie (Langmead et al. 2009) and predicted secondary 
structures by UNAFold (Markham & Zuker 2008) scored using an SVM approach trained 
on fly mirtrons (Chung et al. 2011). All introns of length 50 to 120 nt in Mnemiopsis 
were considered candidate mirtrons (3953 total) and scored by the SVM based on 
secondary structure alone. For every candidate mirtron, I independently counted the 
number of reads pooled from both samples mapping in the correct orientation to the 3’ or 
5’ splice sites, with a three-nucleotide buffer in both directions. My strict read mapping 
criteria was meant to identify the most likely candidates; while mirtron reads can be 
found further from the splice sites in other species, the majority of reads tend to fall in 
this range. I produced three rankings of candidate mirtrons based on the highest scored 
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secondary structures, most correctly mapping reads, and finally by the intersection of the 
two. My results did not uncover any high-confidence mirtron candidates. Scoring of the 
secondary structures resulted in noticeably fewer and lower quality predictions compared 
to scores reported on Drosophila melanogaster and Caenorhabditis elegans introns 
(Chung et al. 2011) (Figure 2.6). 
I analyzed introns up to length 150 nt (7324 additional introns from those length 
50-120 nt) in the case that Mnemiopsis mirtrons, like Amphimedon miRNAs (Grimson et 
al. 2008), were longer than those of flies. The intron length distribution can be seen in 
Figure 2.7. I produced a ranked list based on read counts and manually analyzed the 
secondary structures of the most highly expressed. Again, no acceptable mirtron 
candidates were identified. 
The best candidates had very low read counts and generally hit only one of the 
two splice sites; if they are truly functional mirtrons, they are not expressed at high 
enough levels to be concluded as functional. In addition, their secondary structure 
predictions were less than ideal relative to known mirtrons in other species. The best 
identified mirtron candidate (scaffold ML4098, from 40399-40490 on the ‘+’ strand) 
contains only seven reads total from a single sample (sample 2), six at the 5’ splice site 
and one at the 3’ splice site, and does not have a characteristic loop or 5’/3’ overhang 
structure (see (Maxwell et al. 2012)). 
Annotation of miRNA Pathway Proteins 
RNAi pathway proteins identified in Mnemiopsis throughout the course of this 
study have been deposited in GenBank (http://www.ncbi.nlm.nih.gov/Genbank/), with 
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accessions JQ437405 (Dicer), JQ437406 (Argonaute), JQ437407 (Exportin-5), and 
JQ437408 (Ran). Two additional Argonaute family members were annotated: JX483728 
and JX483729. Identification and annotation of Mnemiopsis proteins was based on high-
scoring reciprocal BLASTP hits to the human RefSeq protein set. TBLASTN was also 
used but did not identify any better candidates. Human Dicer and Drosha both hit 
uniquely to the same Mnemiopsis protein, but reciprocal BLASTP results favored Dicer. 
The protein models of all species represented in Figure 2.5 were searched with HMMER 
3.0 (Finn et al. 2011) for tandem RNase III domains; no Dicer or Drosha candidates were 
identified in the closest non-metazoan outgroups (i.e., Monosiga brevicollis, Salpingoeca 
rosetta, Capsapora owczarzaki and Sphaeroforma arctica). Nematostella, Hydra, 
Trichoplax, and Amphimedon protein sequence data were downloaded from the Joint 
Genome Institute (JGI) Web site and protein sequence data for the closest non-metazoan 
outgroups were downloaded from the Origins of Multicellularity Sequencing Project Web 
site of the Broad Institute of Harvard and MIT (http://www.broadinstitute.org/) in 
November 2011. In some of these species, the RNase III domains of Dicer and Drosha 
proteins were not properly annotated. In these cases, I instead used published, manually 
curated sequences (Grimson et al. 2008) or the appropriate RefSeq entries when those 
were not available. Other RNase III sequences from the bilateria and eubacteria included 
in my analysis were selected from sequences used in a previous study (Cerutti & Casas-
Mollano 2006) or sampled from RefSeq and GenBank. All accession numbers for RNase 
III enzymes included in my final analysis are reported in Table 2.1. The trimmed RNase 
III domain sequences used to build the phylogenetic trees in Figures 2.3 and 2.4 were 
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aligned with HMMER 3.0 (Finn et al. 2011) and manually padded in cases where 
terminal gaps could be reliably filled. Residues 59-98 were manually trimmed from the 
alignment based on poor conservation. 
Figure 2.3 was generated to better-categorize the Mnemiopsis RNase III enzyme 
as a Dicer or Drosha and to better-understand the origin of Drosha. This phylogenetic tree 
was built on the trimmed alignment described above. ProtTest v2.4 (Abascal et al. 2005) 
was used to pick the best model of evolution and selected the LG model with 
optimization of substitution rates, gamma model of rate heterogeneity, and empirical 
amino acid frequencies (PROTGAMMAILGF model). We used RAxML v7.2.8a 
(Stamatakis et al. 2008) to build trees seeded on 24 random starting trees and 24 
maximum parsimony trees. I also ran MrBayes v3.1.2 (Ronquist & Huelsenbeck 2003) to 
construct a Bayesian tree, using five million iterations on five chains with a burn-in factor 
of 25%. MrBayes was run using the second best model selected by ProtTest since the LG 
model is not available in MrBayes: RtRev with optimized substitution rates, gamma 
model of rate heterogeneity, and empirical amino acid frequencies. All 49 trees were 
compared in a maximum likelihood framework, and I reported the tree with the highest 
likelihood (RAxML with maximum parsimony starting tree, log likelihood = -
5895.384778). Support for clades was assessed using 1000 bootstrap replicates and 
posterior probabilities computed with MrBayes.  
!!
83 
Figure 2.6. Mirtron prediction scores histogram by SVM-method, Chung et al. 2011. 
(A) Histogram of D. melanogaster training data. (B) Histogram of M. leidyi predictions.  
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Figure 2.7. Histogram of the intron length distribution over the Mnemiopsis genome. 
3953 out of 69,333 introns are in the expected mirtron length range of [50 − 120] nucleotides. !  
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Table 2.1. RNase III protein sequence identifiers used in the domain phylogenetic trees. 
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CHAPTER 3. SUBMIRINE: ASSESSING VARIANTS IN MICRORNA TARGETS 
USING CLINICAL GENOMIC DATA SETS 
Introduction 
MicroRNAs (miRNAs) down-regulate gene expression endogenously by binding 
to recognition sequences (“target sites”) on mRNAs thereby preventing the target from 
being translated (Bartel 2009). The miRNA regulatory mechanism was discovered in the 
nematode C. elegans in 1993, with the identification of small RNAs encoded by lin-4 
regulating the gene lin-14 through binding in the 3’UTR (R. C. Lee et al. 1993). As 
described in Chapter 2, the miRNA pathway has since been identified in every animal 
except for two of the earliest evolving lineages – the ctenophores and placozoans – and 
many miRNAs (and their target sites) are conserved across species. In humans, the 
number of identified miRNAs is constantly increasing as sequencing technologies 
improve, with current inventories in the thousands (Friedländer et al. 2014; Griffiths-
Jones et al. 2006). 
Many roles have been found for miRNAs in the context of the study and treatment 
of human disease. These include their use as disease biomarkers, as potential therapeutic 
molecules, and as drivers of genetic disease through mutation (Pereira et al. 2012; Soifer 
et al. 2007; Davidson & McCray 2011; B. M. Ryan et al. 2010a; Merritt et al. 2008). 
Genomic variants can alter miRNA functionality through mutation of the primary 
miRNA’s sequence, the miRNA processing machinery (e.g., Dicer, Drosha, and 
Argonaute), or the miRNA’s target sites. Mutations in the processing machinery or 
primary sequence can have severe downstream effects (Merritt et al. 2008; B. M. Ryan et 
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al. 2010a; Clague et al. 2010; Jazdzewski et al. 2008; Duan et al. 2007), whereas 
mutations that occur within miRNA binding sites likely have more subtle, localized 
effects, manifesting as relatively moderate deregulation of gene expression. Thus, the 
mechanistic effects of variants in the miRNA processing machinery and primary 
sequences are relatively easier to predict than variants in miRNA target sites. 
Furthermore, mapping genomic variants onto functional miRNA target sites is 
significantly more difficult than mapping to primary sequences (and the genes encoding 
miRNA-processing proteins), as determining functional loci for miRNA target sites is not 
trivial. The significance of variants in non-coding regions of the genome (Ward & Kellis 
2012) and the role of gene expression in driving human disease phenotypes (Morley et al. 
2004; Emilsson et al. 2008) suggest that variants in miRNA target sites are important to 
human disease susceptibility and progression. It has been shown that miRNA binding 
sites are under selection (Yu et al. 2007; K. Chen & Rajewsky 2006), providing further 
evidence that disrupting their recognition sequences can have significant phenotypic 
effects. Numerous miRNA target site variants (miR-TSVs) have been identified and 
linked to human diseases (Tan et al. 2007; Kulkarni et al. 2011; Kapeller et al. 2008; 
Wynendaele et al. 2010; Sætrom et al. 2009; Y. Li et al. 2014; G. Wang et al. 2008; P. 
Yang et al. 2013; Richardson et al. 2013; Z. Liu et al. 2011; Sethupathy et al. 2007; 
Xiong et al. 2011; Song et al. 2013; Cheng et al. 2013; Miller et al. 2014; Abelson et al. 
2005; Lina Zhang et al. 2011; Y. Lin et al. 2012; Deng et al. 2013; Mishra et al. 2007; L. 
Yang et al. 2012; Adams et al. 2007; Chin et al. 2008; Gao et al. 2009; Brest et al. 2011; 
Jensen et al. 2009), mostly through candidate gene approaches. However, with the 
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increasing number of GWAS hits being identified and with the advancements being made 
to technologies for whole genome-scale analysis in clinical applications, it seems likely 
that many more miR-TSVs will be uncovered. This points to an urgent need for methods 
that can be used to systematically predict miR-TSVs in a genome-wide fashion. 
Despite the fact that miRNAs were discovered over ten years ago, methods to 
confidently identify and predict miRNA target sites are plagued by high false positive 
rates. This is due in large part to our limited knowledge of how miRNA regulation is 
directed. For example, miRNAs have generally been understood to bind the 3’UTR of 
their targets at sites containing perfect Watson-Crick complementarity to the miRNA 
seed region – nucleotides 2-7 (and possibly 8) from the 5’ end of the miRNA. 
Additionally, having an adenine on the 3’UTR across from the first nucleotide of the 
miRNA is thought to enhance the accessibility of RISC (Bartel 2009; Lewis et al. 2005). 
Using these criteria, a six-to-eight nucleotide sequence is generally sufficient for miRNA 
target recognition. Thus, candidate miRNA target sites occur quite frequently, yet very 
few of these are likely to be functional. The increasingly large number of known human 
miRNAs further exacerbates this issue, as it increases the number of unique 6-8mer 
sequences that match putative miRNA target sites. In addition, miRNA binding sites that 
contradict the requirement for perfect seed pairing have been identified (Didiano & 
Hobert 2006), and recent high-throughput screens suggest that such non-canonical 
binding sites (and binding sites outside of the 3’UTR) are potentially more common than 
has been appreciated (Chi et al. 2009; Hafner et al. 2012; Helwak et al. 2013). It is not yet 
clear whether these non-canonical binding sites function to the same degree (or even by 
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the same mechanism) as canonical binding sites, and bioinformatic methods have not yet 
been developed to account for all of their activities. 
Nonetheless, many methods to predict functional versus non-functional miRNA 
target sites have been developed, and their accuracy has been demonstrated by comparing 
their predictions against experimental data (Garcia et al. 2011; Grimson et al. 2007; 
Kertesz et al. 2007; Saito & Sætrom 2010; Krek et al. 2005; Betel et al. 2010; Coronnello 
et al. 2012; Sturm et al. 2010; Yue et al. 2012; Vejnar & Zdobnov 2012; Betel et al. 
2008). These methods utilize features such as site conservation, neighborhood sequence 
context, and thermodynamic properties to distinguish functional sites. As a consequence 
of this complexity, running any one target prediction program genome-wide can be a 
laborious process. Therefore, the predictions made by these methods are generally run 
once on the reference genome, with the results then made available in an online database. 
While having this kind of public resource is helpful for common tasks such as identifying 
known miRNA target sites, it does not address our ability to analyze the effect of 
sequence variants on miRNA functionality. A few of the aforementioned target prediction 
methods provide source code to run custom sequences locally (Grimson et al. 2008; 
Vejnar & Zdobnov 2012; Betel et al. 2008; Kertesz et al. 2007), but analyzing the effects 
of sequence variation on miRNA binding genome-wide is beyond the scope of these 
methods. Historically, clinically associated miR-TSVs have been identified by a 
candidate gene (or SNP) approach, limiting the scale of the search enough to make this 
analysis feasible. Thus, the issues with using these target prediction methods for 
analyzing miR-TSVs are multi-fold: (1) running on a custom data set is non-trivial; (2) 
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running on a custom data set is time consuming; and (3) the methods were not designed 
to run on multiple alleles, so comparing allelic differences must be done manually. While 
tools like PolyPhen-2 (Adzhubei et al. 2010) and SIFT (Ng & Henikoff 2003) have been 
developed for analyzing damaging variants in coding regions of the genome, such tools 
for analyzing lower-impact variants outside of coding regions have not been extensively 
developed [see (Karchin 2009; Fernald et al. 2011) for recent reviews]. 
Recently, a few methods have been developed for analyzing miR-TSVs across the 
genome; however, similar to the target prediction tools, they generally present only the 
results of publicly reported variants and miRNAs in online databases or supplemental 
tables (Hiard et al. 2010; Deveci et al. 2014; Ziebarth et al. 2012; Barenboim et al. 2010; 
C. Liu et al. 2012; Thomas et al. 2011; Bulik-Sullivan et al. 2013). Thus, running these 
methods on custom variants and miRNAs is not supported, limiting their usefulness with 
the large-scale clinical genomic data that is more frequently becoming available. 
Predominantly, existing miR-TSV prediction methods use a target prediction method (as 
described above) to score each allele of a variant and identify miR-TSVs through changes 
in the associated target scores. While this is useful, it does not provide an extensive or 
straightforward approach to prioritize variant effects across the genome, yielding a large 
set of predicted miR-TSVs of unknown significance. In this work, I present a tool called 
SubmiRine that has been designed specifically to address these issues, providing a 
powerful method for systematically analyzing miR-TSVs genome-wide. SubmiRine is an 
open-source software tool designed for clinical genomic data sets that integrates miRNA 
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target prediction, analysis of variant effects, and prioritization of miR-TSV predictions by 
significance, relative to a data set-specific background model. 
Materials and Methods 
Data 
SubmiRine was developed and tested using a large clinical genomic data set 
stemming from the Lung Genome Research Consortium (LGRC) (http://www.lung-
genomics.org/) investigating genetic mechanisms related to chronic lung disease. From 
these data, I utilized a subset of samples that correspond to lung biopsies classified as 
either chronic obstructive pulmonary disease (COPD; 116 samples) or control (43 
samples); matched genotype, gene expression, and miRNA measurements were available 
for all of these samples. First, normalized gene expression data from Agilent microarrays 
was downloaded from GEO (accession GSE47460). Samples were genotyped with the 
Illumina HumanOmni 2.5M Beadchip, which measures ~2.5 million SNPs having MAF 
2.5% or greater, designed around the 1000 Genomes Project data. Lastly, miRNA 
expression was measured via small RNA sequencing with Illumina’s GAIIx and HiSeq, 
normalized to log2 transformed reads per million (RPM) values. Having this type of 
robust clinical genomic data set in-hand provides a powerful opportunity for looking at 
miRNA regulatory variants by integrating multiple relevant data points matched to each 
clinical sample. Specifically, miRNA expression data allows for identification of both 
known and novel miRNAs detected in the sample, as well as their isomiRs (i.e., miRNA 
species processed upstream or downstream of the canonical 5’ locus, producing a miRNA 
with a shifted seed sequence) (Cloonan et al. 2011; Morin et al. 2008), thereby improving 
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our ability to identify known and novel target sites that are likely to be active in vivo. The 
combination of gene expression and genotype data allows for identification of variants of 
clinical interest (through genome wide association), as well as variants that may alter 
gene regulation, thereby being candidate miR-TSVs. Thus, I have used this rich data set 
as a representative of the data that can be utilized from modern, large-scale clinical 
genomic studies with respect to miRNA regulation. I present the results of SubmiRine 
using this data set as a proof-of-concept of my method, but also to predict novel miR-
TSVs that may relate to COPD susceptibility and progression. As the number of genome-
wide association studies (GWASs) continues to grow, leading to the identification of 
more and more human genomic variants associated with disease phenotypes, methods 
such as SubmiRine will allow for the direct evaluation of possible biological mechanisms 
responsible for the underlying phenotype. 
Preprocessing Clinical Genomic Data for Targeted Search of MicroRNA Regulatory 
Variants 
Clinical genomic data sets that integrate genotype, gene expression, and miRNA 
expression information provide an ideal platform for enabling systematic, genome-wide 
identification of functional miR-TSVs. However, no existing method is designed to 
utilize these data for performing dynamic searches of miR-TSVs. SubmiRine was 
designed specifically to harness these data sets for disease context-specific prediction. 
Figure 3.1 represents the standard workflow of SubmiRine that is used in this chapter and 
will be described in the following sections. First, I utilized standard methods for 
analyzing the COPD clinical genomic data to pre-process variants and miRNAs of 
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clinical interest as input for SubmiRine. Specifically, using genotype, gene expression 
data, and RefSeq protein annotations, I first identified cis-eQTLs localized to 3’UTRs 
using MatrixEQTL (Shabalin 2012). This allowed me to focus on variants that 
correspond to a gene expression phenotype consistent with the hypothesis of a functional 
miR-TSV. Second, I used Plink (Purcell et al. 2007) to filter out variants that were not 
associated with the disease phenotype. This step is optional if no disease association is 
being tested. Together, I used these filtered variants to generate a single FASTA 
formatted file containing all candidate 3’UTR alleles and their relative expression. Next, 
normalized miRNA expression values were used to identify candidate miRNAs that are 
present in the sample. A second FASTA formatted sequence file was generated for each 
identified miRNA, with its mean expression recorded. Notably, this allows for isomiRs to 
be considered in addition to canonical miRNAs. These two FASTA files are the output of 
the pre-processing steps for the standard SubmiRine workflow diagrammed in Figure 
3.1A and are the only required input to SubmiRine. Thus, alternative pre-processing 
procedures can be utilized without affecting SubmiRine’s functionality. Furthermore, 
SubmiRine can handle any type of sequence variant and any number of alleles found 
within each 3’UTR, as long as all 3’UTR alleles are aligned. SubmiRine can also handle 
single alleles in 3’UTRs for traditional miRNA target site identification purposes. Sample 
input files and the source code can be found online at 
http://research.nhgri.nih.gov/SubmiRine. 
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Figure 3.1. The standard SubmiRine workflow. 
(A) Pre-processing steps used to select candidate variants (the “Test Model”) and decoy variants (the “Background 
Model”) for miR-TSV prediction. The SubmiRine_Search module is then run independently on (B) the Test Model and 
(C) the Background Model. SubmiRine_Search takes two FASTA files as input, one for 3’UTRs and one for miRNAs, 
and each FASTA record contains representative expression values. SubmiRine_Search outputs the scored set of 
candidate miR-TSVs identified in the input model. (D) The SubmiRine_Compare module is then used to prioritize the 
miR-TSVs from the Test Model by comparing them to the decoy miR-TSVs from the Background Model. 
SubmiRine_Compare computes the SLP score (Sum of Log-scaled Probabilities), representing the joint, empirical 
probability of the scores computed for each candidate miR-TSV. 
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Prediction of Variant Allele-specific MicroRNA Target Binding Sites 
SubmiRine identifies and prioritizes candidate miR-TSVs using a multi-step 
process. The first step involves the SubmiRine_Search module, using the pre-processed 
clinical data as its input (Figure 3.1B). First, candidate miRNA target sites are identified 
on all 3’UTR alleles in preparation for scoring with TargetScan6 context+ scores 
(Grimson et al. 2007; Garcia et al. 2011). Context+ scores require that miRNA binding 
sites be canonical 6mer, 7mer-1a, 7mer-m8, or 8mer sites. Thus, the identification of all 
candidate binding sites requires searching for all 6-8mer sequences corresponding to the 
seed sites of the input set of expressed miRNAs. SubmiRine performs this search rapidly 
against a Burrows-Wheeler transform of the input 3’UTR sequences. Once all candidate 
miRNA binding sites are identified, each context+ score is computed using the sequence 
neighborhood surrounding each site. 
Multiple studies have demonstrated the importance of miRNA abundance in 
predicting functional target sites (Stadler et al. 2012; Mullokandov et al. 2012; 
Coronnello et al. 2012). Logically, a miRNA must be present and expressed at high 
enough levels to significantly repress its targets, and individual targets must compete for 
available miRNAs. Thus, after predicting all context+ scores, SubmiRine utilizes miRNA 
expression values in order to weight target scores by abundance of the candidate miRNA. 
This is computed by multiplying the miRNA’s normalized expression value by the raw 
context+ score of each candidate binding site. The raw context+ score is referred to as the 
“binary score,” and the miRNA abundance-weighted score is referred to as the “empirical 
score.” SubmiRine retains both the binary and empirical scores, as they each may be 
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meaningful for assessing candidate miR-TSVs. For example, given that miRNA 
abundance values can vary significantly between miRNA species, the most highly 
expressed miRNAs (e.g., let-7) can generate extremely high empirical scores for very low 
scoring candidate targets. Thus, while the empirical score has been shown to reduce false 
positive rates (Coronnello et al. 2012), the unweighted binary score is also important to 
consider. 
After all candidate target sites have been identified and scored, SubmiRine 
compares all target sites across the set of alleles for a particular 3’UTR and identifies 
miRNA target sites whose score differs in at least one allele. If a target site does not exist 
on a particular allele, its score is considered to be zero. This score difference allows for 
identification of variants that create or destroy miRNA binding sites altogether, as well as 
variants that merely alter the predicted binding strength of a particular miRNA between 
alleles. Collectively, these variant-miRNA pairs represent the set of candidate miR-TSVs. 
Finally, because the input 3’UTR alleles were derived from cis-eQTLs and therefore have 
allele-specific expression values, SubmiRine ignores all candidate miR-TSVs that have 
scoring differences inconsistent with the direction of change in gene expression. 
Following this comparison, SubmiRine produces one output file containing all of the raw 
target site predictions (with both binary and empirical scores), and a second output file 
reporting only candidate miR-TSVs with target site scoring differences between alleles. 
miR-TSVs are reported by their change in binary and empirical score (Δbinary and 
Δempirical), and the scores of the strongest target site (i.e., the most negative) in the 
allele group are also reported. Additionally, two similar files are produced where all 
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target sites for a particular miRNA that occur in the same UTR are summed, representing 
a miRNA-wise (“mir-wise”) view of target prediction opposed to the site-specific (“site-
wise”) view described above [see (Krek et al. 2005; Betel et al. 2010; Garcia et al. 2011; 
Sumazin et al. 2011) for more detail]. In this chapter, I focus on the site-wise predictions 
because there is not a large density of SNPs per 3’UTR, but the mir-wise predictions are 
produced for cases where they may provide more global information relative to site-wise 
predictions. 
Defining a Background Model with Decoy Variants 
The list of candidate miR-TSVs identified in the SubmiRine_Search module can 
be quite large, especially for sets of 3’UTRs and miRNAs generated from genome-wide 
scans. Thus, determining which miR-TSVs are the most likely to be functional (and have 
the strongest impact) requires prioritizing the list of predicted miR-TSVs. SubmiRine 
prioritizes the predicted miR-TSVs by comparing them to a background model consisting 
of decoy 3’UTR variants. Here, decoy variants are defined as genomic variants that occur 
in a 3’UTR but do not correlate with allele-specific gene expression. Because SubmiRine 
was designed to run on custom clinical genomic data sets, the decoy variant set can be 
generated alongside the clinically relevant set during standard pre-processing (Figure 
3.1A).  
During pre-processing, I identified local 3’UTR cis-eQTLs (i.e., variants in 
3’UTRs whose genotype is correlated with expression of the underlying gene) to select 
variants that may be functional miR-TSVs. MatrixEQTL models the genotype-gene 
expression interaction as a quantitative trait using a linear model (or, optionally, a 
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variation-based model), and assigns a p-value to each variant based upon its probability 
of being a true eQTL. While likely eQTLs are selected on the lower tail of this p-value 
distribution where p ≈ 0 (I used a cutoff of FDR = 0.05), unlikely eQTLs are conversely 
predicted on the upper tail of the distribution where p ≈ 1. These correspond to variants 
that do not fit a linear model relative to the gene expression quantitative trait, or fit a 
linear model with a slope ≈ 0. Thus, the background model contains a set of 3’UTR 
variants that lie on the upper tail of the p-value distribution produced by MatrixEQTL, 
representing true decoy variants. This approach is preferable to using simulated sequence 
variants for the background model because it utilizes observed variants that show 
experimental evidence of being non-functional miR-TSVs, making them much more 
representative of true negative examples. Using this set of 3’UTRs with decoy variants 
(i.e., the background model), SubmiRine_Search is run a second time in the same fashion 
as for the clinically relevant set to generate decoy miR-TSVs (Figure 3.1C). These decoy 
miR-TSVs can be used to determine, for each miRNA, how often particular target site 
scores (and variant-driven scoring changes) occur in a non-functional, background model. 
Prioritizing Predictions by MicroRNA Regulation-altering Potential 
Qualitatively, to prioritize predicted miR-TSVs for further clinical study, each 
candidate miR-TSV should be assessed for the repressive strength of the created (or 
destroyed) binding site, the magnitude of the variant’s effect on miRNA binding, the 
availability (abundance) of the miRNA, and the relative significance of these metrics 
compared to others in the genome. SubmiRine utilizes the background model to make 
these assessments quantitatively in the SubmiRine_Compare module (Figure 3.1D). 
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Specifically, for each predicted miR-TSV from the clinically relevant set (Figure 3.1B), 
SubmiRine compares the binary score, empirical score, Δbinary score, and Δempirical 
score to the distribution of corresponding metrics observed in the decoy (non-functional) 
miR-TSVs (Figure 3.1C). Using these four scoring metrics, SubmiRine_Compare 
computes a total of six empirical probabilities reflecting how common each metric for a 
candidate miR-TSV is expected to be in non-functional data. The six probabilities of this 
form are defined in Table 3.1. In practice, a series of empirical cumulative distribution 
functions (eCDFs) are built with the background model to compute these probabilities 
directly. To prevent probabilities of 0 and 1, each eCDF contains two extra pseudocount 
values (one above the observed maximum and one below the observed minimum) such 
that empirical probabilities follow Laplace’s rule of succession. Note that two of the six 
empirical probabilities are computed relative to a background set containing only the 
subset of decoy miR-TSVs that correspond to the miRNA associated with the candidate 
miR-TSV being tested; this allows SubmiRine to model competition among sites of a 
particular miRNA implicitly. 
Once these six empirical probabilities have been computed against the 
background model, SubmiRine_Compare computes the product of all six probabilities to 
produce a single, combined metric by which all predictions can be prioritized. I call this 
metric the SLP (Sum of Log-scaled Probabilities) score, computed as a natural log. Thus, 
I consider each of the probabilities to be equally weighted, as the scoring scheme is 
unsupervised. To improve this metric would require a large number of validated 
predictions to distinguish true from false positives, yet no such data set currently exists. 
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However, I have found that the unweighted product performs well with the set of known 
miR-TSVs I was able to test, suggesting all six empirical probabilities are meaningful and 
have predictive value (see Results). !  
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Table 3.1. Definitions of SubmiRine metrics and empirical probabilities. !  
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Implementation Details 
In order to accommodate large-scale, clinical genomic data sets, SubmiRine was 
designed to be an open-source program that can run efficiently on a single processor with 
sufficient RAM. Comparatively, every existing target site and miR-TSV prediction 
method is primarily presented as a pre-computed database and are not designed for runs 
with custom sequence data in the context of a high-throughput analysis pipeline (Betel et 
al. 2010; Grimson et al. 2007; Krek et al. 2005; Coronnello et al. 2012; Thomas et al. 
2011; Deveci et al. 2014; C. Liu et al. 2012; Bruno et al. 2012; Ziebarth et al. 2012; 
Barenboim et al. 2010; Hiard et al. 2010). To my knowledge, several target prediction 
methods do provide open-source code that can be installed and run locally (Betel et al. 
2008; Kertesz et al. 2007; Grimson et al. 2007; Vejnar & Zdobnov 2012), but no such 
miR-TSV prediction tool currently exists. Genome-wide scans using the open-source 
target prediction tools mentioned above are inefficient in the context of an analysis 
pipeline, as they require scanning the genome once for every input miRNA to identify 
candidate target sites. Additionally, many require computationally intensive steps within 
the scoring framework, including miRNA-to-target sequence alignments (Betel et al. 
2008; Grimson et al. 2007; Kertesz et al. 2007; Vejnar & Zdobnov 2012), secondary 
structure predictions (Kertesz et al. 2007; Betel et al. 2008; Vejnar & Zdobnov 2012), 
and analysis of target site conservation across species (Grimson et al. 2008; Vejnar & 
Zdobnov 2012). To perform target prediction efficiently in SubmiRine, I utilized 
TargetScan6 context+ scores for a few reasons. First, context+ scores are computed 
independently of target site conservation, making them well-suited for scoring variant 
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effects in miRNA targets, but also avoiding the need to align input 3’UTR sequences 
across species. Second, context+ scores are based on candidate target sites that follow the 
rules of canonical seed pairing (i.e., 6mer, 7mer-1a, 7mer-m8, or 8mer target sites). This 
allows miRNA binding site candidates to be identified via simple string searches, where 
the number of search strings is linear with respect to the size of the input miRNA set. 
Thus, SubmiRine indexes the full set of 3’UTR sequences with a Burrows-Wheeler 
transform, allowing all candidate target sites to be identified rapidly without scanning the 
genome once for every miRNA. If necessary, future versions of SubmiRine could 
incorporate certain non-canonical seed sites (such as bulge sites (Helwak et al. 2013)) by 
extending the set of possible seed sequences for each miRNA. SubmiRine utilizes the 
open-source ‘py-burrows-wheeler’ implementation of the Burrows-Wheeler algorithm 
(http://code.google.com/p/py-burrows-wheeler/). Third, TargetScan6 context+ scores do 
not require ad hoc RNA secondary structure predictions, which are computationally 
expensive – especially when analyzing a large set of miRNAs and 3’UTRs. Although 
secondary structure predictions are not performed, the ‘AU content’ metric that 
contributes to TargetScan6 context+ scores has been shown to be highly correlated with 
free energy estimates of target site accessibility (i.e., ΔG-open) (Kertesz et al. 2007; 
Vejnar & Zdobnov 2012). Also, the seed-pairing stability (SPS) metric pre-computed for 
TargetScan6 context+ scores reflects the free energy estimate of miRNA seed/target 
binding. Therefore, my use of TargetScan6 context+ scores does consider secondary 
structure information to some extent, but without the caveat of having to predict binding 
structures on the fly. TargetScan6 context+ scores do require minimal miRNA-to-target 
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sequence alignment in order to assess 3’ supplemental pairing contributions, and this step 
remains the most intensive part of SubmiRine, consuming over half of the runtime. 
Together, these implementation details greatly improve scalability for genome-wide 
target prediction. 
SubmiRine utilizes a Python implementation of TargetScan developed within the 
framework of the miRmap tool (Vejnar & Zdobnov 2012), with modifications to account 
for a more recent version of TargetScan (version 6) that includes the seed pairing stability 
and miRNA target abundance scoring features (Garcia et al. 2011). While miRmap has 
external library dependencies for certain scoring features, SubmiRine does not utilize 
these libraries for TargetScan scoring, and therefore does not require such dependencies. 
The core scoring algorithm in the SubmiRine framework is the SubmiRine_Search 
module written in Python, which is designed to run on either a clinically relevant set of 
3’UTRs or a background model of decoy 3’UTR variants. In most cases (including the 
application described in this chapter), it is desirable to compare the output of the 
clinically relevant set against the background model and compute the empirical 
probabilities used for miR-TSV prioritization. This is performed with the 
SubmiRine_Compare module – an independent R script – that accepts two output files 
from the SubmiRine_Search module as input (i.e., the output from the clinically relevant 
model and the background model). 
Performance 
As described above, the majority of existing target prediction and miR-TSV 
prediction tools are not open-source, so I could not compare the efficiency of SubmiRine 
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to all of these methods. However, I was able to compare the miRNA target site search 
and scoring steps of SubmiRine to the equivalent steps of TargetScan6 (context+ scores 
only) (Grimson et al. 2007; Garcia et al. 2011), miRanda (Betel et al. 2008), and PITA 
(Kertesz et al. 2007). As a benchmark data set, I used all 3’UTR sequences in Ensembl 
that have corresponding RefSeq protein identifiers and generated two alleles per 3’UTR 
by adding a single, simulated SNP or single-nucleotide deletion on each UTR. This 
included 18605 3’UTRs that are found genome-wide, resulting in 37210 3’UTR alleles. 
In total, this dataset comprised roughly 47.62 Mb of sequence. As the miRNA input set, I 
utilized all mature sequences for human miRNAs from miRBase (Griffiths-Jones et al. 
2006), representing 2042 miRNA species at the time of this writing. I anticipated that this 
benchmark data set would represent the largest input data set that might be used, although 
it is significantly larger than what I generated from the COPD clinical genomic data set. 
Comparatively, with the COPD data, the test and background models contain 8.08 Mb 
and 336.6 Kb of 3’UTR sequence, respectively, and 418 miRNAs were identified with 
expression above 10 RPM (see above). 
In order to make a fair comparison between different methods, I searched only for 
canonical 7-8 nucleotide seed sites with each method, allowing no mismatches or GU-
wobbles (-strict option in miRanda). As SubmiRine performs additional functions 
beyond target site identification and scoring, I only considered runtime through these 
steps, which are restricted to the SubmiRine_Search module. Specifically, this includes 
the computation of the Burrows-Wheeler Transform, candidate target site searching, and 
scoring with context+ scores. Notably, PITA was not scalable to this large of a dataset, so 
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I calculated its runtime on a small sample of the input 3’UTR sequences (all miRNAs) 
and extrapolated its runtime accordingly. SubmiRine processed the benchmark data set in 
2.35 hours, representing a more than six-fold increase in speed relative to the next fastest 
comparison tool (TargetScan6, at 14.16 hours), and speed improvements of roughly 11-
fold and 400-fold to miRanda (26.26 hours) and PITA (1023.59 estimated hours), 
respectively. These speed-ups are not surprising given the computationally intensive 
secondary structure and sequence alignment steps performed by miRanda and PITA, but 
the improved speed when compared to TargetScan6 is purely a result of faster candidate 
target site identification via the use of a Burrows-Wheeler transform in SubmiRine. 
Because SubmiRine has to compare target sites to identify miR-TSVs, each 
candidate target site must be stored in memory; thus, the memory footprint can be quite 
large, scaling linearly with the number of targets identified. Thus, one can compute a 
rough estimate of the memory (RAM) requirements a priori by estimating the expected 
number of target sites, which is a function of the amount of UTR sequence and the size of 
the input miRNA set being analyzed (i.e., an estimate of the proportion of k-mers that 
will match a miRNA seed site, extrapolated according to the amount of UTR sequence). 
Realistically, the true number of target sites identified will also be dependent on the 
redundancy of the input miRNA set and the non-randomness inherent to UTR sequence 
data, and additional memory overhead is required outside of storing target sites. 
Nonetheless, my runs on the benchmark and COPD data sets suggest that 3-5 Kb of RAM 
per expected target site is required for larger data sets, where the number of expected 
target sites, E[|T|], is computed by the equation: 
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where M is the number of miRNAs, S is the minimum seed site length, D is the amount of 
DNA sequence (in bases), and U is the number of UTR records. Peak memory usage was 
25.4 Gb for the benchmark data set, 2.4 Gb for the COPD background model, and 263.4 
Mb for the COPD eQTL test model. Thus, for general clinical genomic data use cases, a 
standard desktop or laptop should have sufficient memory, but larger machines may be 
required for unfiltered, genome wide searches. 
Results 
COPD 
SubmiRine was run on the COPD clinical genomic data set following the pipeline 
illustrated in Figure 3.1. The preprocessing steps produced a total of 93 3’UTRs 
containing 127 SNPs in the target model and 1608 3’UTRs containing 2106 decoy SNPs 
in the background model. Concurrently, I applied a threshold to include only miRNAs 
that were expressed at a level of 10 RPM or higher in at least one of the samples in the 
cohort, and the mean expression was recorded across the cohort as the representative 
expression value. This produced a total of 418 miRNAs. Using these pre-processed data, 
SubmiRine produced 467 putative miR-TSVs that were consistent with the expression 
changes reported in the eQTL models (out of 1074 miR-TSVs total), with SLP scores 
ranging from -0.875 to -26.074. The top 12, non-redundant predictions are presented in 
Table 3.2, with the top prediction further detailed in Figure 3.2. 
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The highest scoring predictions presented in Table 3.2 represent a broad range of 
potential miR-TSVs. For example, SNPs that are predicted to alter the sequence 
neighborhood of very strong target sites for highly expressed miRNAs represent miR-
TSVs that have a relatively indirect effect on miRNA binding. In contrast, other high 
scoring predictions directly create or abolish a strong miRNA seed site, but do so for 
moderately expressed miRNAs. It is unclear if either of these characteristics should be 
more heavily weighted than the other or if they are equally important. Additionally, I 
highlight the fact that two of the top miR-TSV predictions are not based on the canonical 
mature miRNA, but rather on an isomiR. 
To further demonstrate the results obtained from SubmiRine, Figure 3.2 
summarizes the data behind the highest scoring miR-TSV prediction: the creation of a 
miR-363-3p isomiR binding site by the A/G SNP rs7322 on the 3’UTR of SPG21. Figure 
3.2A displays the secondary structure of the primary miR-363 locus (pri-miR-363), along 
with the quantified mature miRNA reads mapped to this region. Note that the canonical 
mature miR-363-3p exhibits the largest read population of 132.2 reads per million (rpm) 
and that the 5’ shifted isomiR miR-363-3p(+1) is also moderately expressed at 13.5 rpm. 
Next, the two alleles of rs7322 are displayed within the SPG21 3’UTR, and the only 
predicted miRNA target site occurring between these miRNA and 3’UTR combinations 
is highlighted: rs7322(A) and miR-363-3p(+1). Thus, the canonical form of miR-363-3p is 
not predicted to target this locus on SPG21, but the miR-363-3p(+1) isomiR is predicted to 
bind the rs7322(A) allele (binary score = -0.3714) and not the rs7322(G) allele (binary 
score = 0). The six empirical probabilities and SLP score computed by SubmiRine for 
!!
109 
this miR-TSV are shown. P1 shows that, relative to all target sites in the background 
model, this binary score is “stronger” than over 99.4% of the decoy target sites. However, 
when considering only other potential target sites for miR-363-3p(+1), P2 demonstrates 
that this site is stronger than 99.9% of the decoy target sites. Thus, P2 demonstrates that 
this particular site is predicted to be highly competitive for available miR-363-3p(+1). 
Because this isomiR is not particularly highly expressed, the empirical score (P3) is not 
quite as significant as the binary score (P1). Probabilities P4-P6 show that the Δbinary and 
Δempirical scores correspond to similar levels of significance as those described above. 
Figures 3.2B and 3.2C demonstrate the relevance of rs7322 to the COPD clinical 
phenotype. Figure 3.2B demonstrates that the genotype at rs7322 is associated with 
differential SPG21 expression levels (p=1.53 x 10-15), with the rs7322(A) allele 
corresponding to lower expression, consistent with the miR-TSV prediction. I note that 
the expression of miR-363-3p(+1) does not significantly differ among the rs7322 genotype 
subpopulations (data not shown), rejecting the possibility that the observed rs7322-
SPG21 eQTL is an artifact of varying miR-363-3p(+1) levels. Finally, Figure 3.2C shows 
that the rs7322(A) allele is more frequent in the COPD cases than in the controls 
(p=0.0373), suggesting this miR-TSV prediction could be associated with COPD 
susceptibility. Together, these results demonstrate that the top predictions by SubmiRine 
on the COPD data set appear to be consistent with a potentially functional and clinically 
relevant miR-TSV and may warrant experimental verification.  
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Table 3.2. Top COPD-related miR-TSV predictions by SubmiRine. 
The gene, SNP, and miRNA for each of the top 12 non-redundant miR-TSVs predicted by SubmiRine on the COPD 
data set are displayed. Each miRNA’s mean expression is reported in reads per million (rpm), along with the predicted 
effect of each miR-TSV and SLP score. The full list of COPD miR-TSV predictions can be found in (Maxwell et al. 
submitted). !  
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Figure 3.2. Highest-scoring miR-TSV prediction on the COPD data set. 
(A) The primary miR-363 locus and secondary structure are displayed, along with the quantified miRNA-Seq reads 
mapping to this region. Also shown is the locus on the 3’UTR of SPG21 containing the rs7322 SNP. Highlighted in 
green is the predicted 8mer miRNA target site predicted on the rs7322(A) allele only for the miR-363-3p(+1) isomiR. 
Based on the SLP score computed by SubmiRine, this represents the highest-scoring miR-TSV prediction the COPD 
dataset (see Table 1). (B) The rs7322 cis-eQTL relationship with SPG21. Consistent with the predicted miR-TSV in A, 
the rs7322(A) allele is associated with lower SPG21 expression. (C) The rs7322(A) allele is also moderately associated 
with the COPD phenotype, being more frequent in cases than controls. !!  
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Validation of Known SNPs Affecting miRNA Target Sites 
In order to assess the accuracy of SubmiRine, I tested its ability to predict and 
prioritize known miR-TSVs alongside the novel predictions made from the COPD 
clinical data. Currently, many miR-TSVs have been reported in the literature, but only a 
handful have been experimentally validated to the point of demonstrating functional, 
allele-specific miRNA regulation in vivo. Since the goal of SubmiRine is to both predict 
miR-TSVs and prioritize them by their probability of being functional, I utilized only 
known miR-TSVs that have been experimentally validated in the “test set”. In total, I 
identified 26 such cases in the literature (Tan et al. 2007; Kulkarni et al. 2011; Kapeller et 
al. 2008; Wynendaele et al. 2010; Sætrom et al. 2009; Y. Li et al. 2014; G. Wang et al. 
2008; P. Yang et al. 2013; Richardson et al. 2013; Z. Liu et al. 2011; Sethupathy et al. 
2007; Xiong et al. 2011; Song et al. 2013; Cheng et al. 2013; Miller et al. 2014; Abelson 
et al. 2005; Lina Zhang et al. 2011; Y. Lin et al. 2012; Deng et al. 2013; Mishra et al. 
2007; L. Yang et al. 2012; Adams et al. 2007; Chin et al. 2008; Gao et al. 2009; Brest et 
al. 2011; Jensen et al. 2009) (see Table 3.3). Using this test set, I evaluated SubmiRine’s 
ability to identify known miR-TSVs as well as to efficiently prioritize them via the SLP 
score, highlighting miR-TSVs (both known and novel COPD predictions) that are the 
most likely to be functional. 
Despite my relatively strict criteria for selecting cases for the test set, I anticipate 
that some of the validated miR-TSVs I include could be false positives. Validation of 
miR-TSVs is often demonstrated in vitro through over-expression of the candidate 
miRNA, yet miRNA expression levels have been shown to affect the ability of target 
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genes to be repressed (Mullokandov et al. 2012; Coronnello et al. 2012). Thus, over-
expressing a miRNA beyond normal physiological levels could produce false positive 
interactions. Furthermore, many validated miR-TSVs were first identified in silico using 
a single candidate gene and the entire set of miRNAs annotated in miRBase (Griffiths-
Jones et al. 2006), which may include many tissue-specific and low-confidence miRNAs 
not relevant to the clinical phenotype. For example, rs3134615, which lies in the 3’UTR 
of MYCL1, was predicted to have allele-specific expression due to binding of miR-1827 
to the G allele only, which is associated with small-cell lung cancer (Xiong et al. 2011). 
However, miR-1827’s expression was not validated in vivo, and there is very minimal 
experimental evidence for miR-1827 presented in miRBase, suggesting it may not even 
be a real miRNA. Nonetheless, transfection of a miR-1827 construct successfully 
repressed MYCL1 in an allele-specific fashion. 
Starting with the 26 miR-TSVs in our test set, I filtered out any miR-TSVs where 
the associated SNP was not included in our input 3’UTR data, as well as miR-TSVs 
corresponding to non-canonical target sites, which cannot be scored by the TargetScan 
context+ scores utilized in SubmiRine. In total, these filtering steps removed seven miR-
TSVs from the test set, including four cases of non-canonical seed sites, two SNPs that 
do not map to 3’UTRs, and one SNP whose record is deprecated in dbSNP and could not 
be mapped (see Table 3.3). Of the 19 remaining test miR-TSVs, five correspond to 
miRNAs that were not identified in the lung tissue samples (miR-367, miR-510, miR-
513a, miR-1827, and miR-3148), and one was expressed below my cutoff threshold of 10 
RPM (miR-433). Thus, for each test miR-TSV, if the miRNA was identified above 10 
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RPM in the lung tissue samples, I utilized the detected mean expression value; otherwise, 
I “simulated” the miRNA’s expression by imputing it into our COPD data set at a 
moderate expression level of 100 RPM. Note that, with the exception of miR-1827, all of 
the miRNAs for which expression was simulated were shown to be expressed in the 
respective miR-TSV study, supporting the fact that some miRNAs are tissue-specific and 
simply may not have been detected in the lung. While these miRNA expression values 
could be specific to lung tissue, I nonetheless used these values as a proxy for the relative 
expression of each miRNA in vivo so that the test miR-TSVs could be scored alongside 
the COPD predictions. 
To test the 19 remaining validated miR-TSVs, I added the 3’UTRs of each test 
miR-TSV into the COPD data set of eQTLs, using dummy expression values to reflect 
the allele predicted to have lower expression. I then ran SubmiRine on the COPD data 
merged with the validated miR-TSVs and compared the results side-by-side. Figure 3.3 
and Table 3.3 show that SubmiRine identified all 19 test miR-TSVs, but reported two as 
false positives (i.e., having a SLP score of zero). Both of these cases (rs12537 and 
rs3853839) correspond to miR-TSVs where the TargetScan context+ score of the target 
site is greater than zero, corresponding to a prediction of a non-functional target site. 
Surprisingly, both of the publications reporting these miR-TSVs used TargetScan to 
identify the putative target sites, but included the sites despite their positive scores (Y. 
Lin et al. 2012; Deng et al. 2013). These cases either represent false negatives from 
TargetScan or false positives due to non-physiological experimental conditions during 
validation. In fact, in the case of rs12537, the comparison of expression levels between 
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MTMR3 alleles was not significant in all cases and did not show differential expression 
following transfection of miR-181 inhibitors as expected. In the case of rs3853839, the 
G-allele (predicted to disrupt the target site) also shows significant repression as a result 
of miR-3148 transfection, suggesting binding may not be specific and may be the result 
of miRNA saturation. 
The majority of the 17 test miR-TSVs with a non-zero SLP score were very 
highly scored by SubmiRine. Two of the 17 scored higher than any predicted miR-TSV 
from the COPD set, including the miR-148 binding sites on HLA-C and HLA-G. The 
miR-148 binding site in HLA-C is altered by rs67384697, which encodes a single 
nucleotide deletion. Thus, recovery of this validated SNP demonstrates that SubmiRine 
can successfully handle indel variants. Also among the highest scoring predictions are the 
miR-191 binding site on MDM4, the miR-125 binding site on BMPR1B, and the miR-510 
binding site (with simulated expression) on HTR3E. Two of the three lowest-scoring test 
miR-TSVs correspond to SNPs that do not alter the seed region of the predicted target 
site but still manage to score in the 66th and 85th percentile, respectively, of all miR-TSVs 
predicted in the COPD data; rs1044129 slightly alters the AU content of the 
neighborhood surrounding the target site, and rs193302862 increases the 3’ supplemental 
pairing of the miR-24-5p target site. The other fifteen test miR-TSVs are predicted to 
alter the target’s seed region, with two altering the seed type (e.g., 6mer to a 7mer-m8 
site) and the other thirteen completely destroying (or creating) a seed site. These results 
indicate that SubmiRine is able to identify and highly prioritize experimentally validated 
miR-TSVs. Notably, these results demonstrate that miRNA abundance influences 
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SubmiRine SLP scores without overwhelming them. Validated miR-TSVs that 
correspond to lowly expressed miRNAs are still recovered at relatively high SLP scores, 
and simulated miR-TSVs reflect a broad range of SLP scores despite having equivalent 
levels of miRNA expression (Figure 3.4). Furthermore, considering these validated miR-
TSVs alongside predicted miR-TSVs from the COPD data helps contextualize the 
strength of the novel predictions from the clinical genomic data. !  
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Table 3.3. Experimentally validated miR-TSVs. !  
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Figure 3.3. SubmiRine SLP score distribution of known miR-TSVs and predicted COPD-related miR-TSVs. 
Histogram showing the number of candidate miR-TSVs predicted at different SLP score cutoffs from the COPD data 
set relative to the test set of known miR-TSVs identified in previous studies. The test set (Table 3.3) is divided into 
subsets representing known miR-TSVs whose miRNA was identified in our lung samples (“Test”), and known miR-
TSVs whose miRNA was not identified (or identified below our RPM threshold) in our lung samples, resulting in its 
expression being simulated at 100 RPM [“Test (Simulated)”]. !
Figure 3.4. SLP score distribution relative to miRNA abundance. 
Scored miR-TSV predictions from COPD and Test data sets (see Figure 3.3) stratified by miRNA abundance in reads 
per million (RPM). !  
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Using SubmiRine to Predict Novel miRNA Binding Site Alterations in Validated SNPs 
In addition to recovering 17 known miR-TSVs, SubmiRine identified a handful of 
additional high-scoring predictions on the 3’UTRs from test miR-TSVs for 
uninvestigated miRNAs (Figure 3.5). First, I predicted that the SNP rs4245739 found in 
MDM4 with C allele-specific binding to miR-191 also has an overlapping binding site 
predicted for miR-887, which has almost as strong of a predicted effect. Second, in HLA-
C, the deletion encoded by rs67384697 is reported as part of a larger haplotype (Kulkarni 
et al. 2011). I investigated additional variants in this region, and predicted that the G>T 
SNP at position 324 of the aligned UTR (Kulkarni et al. 2011) creates a very strong 
binding site for two miRNAs that overlap in seed sequence: miR-146 and miR-589. 
Interestingly, because SubmiRine uses miRNA-Seq reads to define candidate miRNAs, 
we also detected a substantial level of an isomiR of miR-146 (miR-146(-1), which is 
processed one nucleotide upstream on the 5’ end of the canonical miR-146), and 
predicted that 324G enhances the binding of the miR-146 isomiR to HLA-C by altering a 
7mer-1a site to an 8-mer site. The original study on HLA-C investigated other SNPs in 
this region and showed experimentally that they did not alter miRNA functions, but this 
particular SNP at position 324 and the corresponding miRNAs were not reportedly tested. 
While these novel predictions may be influenced by our use of miRNA expression values 
from lung tissue, these miRNAs are all reported as relatively highly expressed in 
miRBase (Griffiths-Jones et al. 2006) and may be worth investigating further to 
determine the degree to which they contribute to their respective disease mechanisms. !  
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Figure 3.5. Novel miR-TSV predictions on variants of previously validated miR-TSVs. 
Using the miRNA expression data from the COPD data set, SubmiRine predicted novel high-scoring candidate miR-
TSVs on MDM4 and HLA-C in addition to the experimentally validated miR-TSVs reported in the original studies (see 
Table 3.3). !  
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Discussion 
In this work, I present the tool SubmiRine, which I have developed for analyzing 
miRNA target site variants (miR-TSVs) identified in clinical genomic data sets. 
SubmiRine is an open-source computational framework written in Python and R that 
allows researchers the ability to efficiently predict both miRNA target sites and miR-
TSVs on a genome-wide scale. Furthermore, it provides a scoring mechanism for 
prioritizing miR-TSVs that are more likely to be functional. I demonstrated SubmiRine’s 
effectiveness using both a novel COPD clinical genomic data set and a set of known 
miR-TSVs that have been validated elsewhere. Using the clinical genomic data, I have 
predicted a number of miR-TSVs that may indeed be functional. This includes novel 
predictions related to COPD, but also a handful of alternative miR-TSV predictions that 
may coordinate with known miR-TSVs from our validation set. SubmiRine’s scoring 
scheme is based on empirical probabilities computed relative to a background model of 
decoy variants. I show that known miR-TSVs score highly relative to novel predictions in 
COPD, demonstrating that SubmiRine’s SLP score has high precision. 
To my knowledge, SubmiRine is the first miR-TSV prediction tool developed to 
analyze clinical genomic data sets in a high-throughput fashion. Existing tools are limited 
to pre-computed predictions reported in an online database and do not have a mechanism 
to prioritize predictions relative to expected functional significance. SubmiRine is 
designed specifically for such clinical contexts and, in addition to providing more 
informative output, is shown to be much faster than existing target prediction tools. 
SubmiRine’s underlying use of TargetScan6 context+ scores enables identification of 
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miRNA target sites having canonical seed site sequences (6-8mers), which I show 
encompass the majority of known miR-TSVs. While a subset of known miR-TSVs from 
the validation set do not correspond to canonical miRNA seed sites or do not fall in 
3’UTRs, I expect that canonical 3’UTR miR-TSVs will tend to have the strongest effects, 
especially from a genome-wide perspective. Previous reports have shown that non-
canonical target sites and target sites outside of the 3’UTR tend to be less repressive 
(Hafner et al. 2010). However, as the community’s understanding of miRNA regulation 
by these alternative mechanisms improves, SubmiRine’s scoring method can be easily 
adapted. 
As genomic data begins to work its way into more clinical settings, the need for 
high-throughput tools to assess genomic variants of clinical importance is becoming 
imperative, particularly given how the widespread use of genome-wide association 
studies (GWASs) to identify variants associated with a given condition has become 
standard practice. However, the vast majority of GWAS hits are not associated with 
specific biological mechanisms, greatly limiting their potential use for development of 
therapeutics. It is hoped that tools such as SubmiRine – ones that can be used in the 
context of real genomics use cases to assess the effect of a specific kind of variation – can 
speed up the process of identifying promising targets worthy of experimental verification, 
with an eye towards downstream translational studies having tangible clinical 
applicability. 
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CONCLUSIONS 
 In this dissertation, I have presented studies investigating multiple biological 
functions, their evolution, and their relationships to human diseases. First, I surveyed the 
evolutionary origins of human disease genes across a broad range of animal species 
whose genomes have been sequenced and demonstrated that, comparatively, different 
classes of human disease genes have heterogeneous evolutionary origins. I showed that 
the genetic age distribution for a disease class is correlated with the degree of purifying 
selection acting on the same genes between mammals and humans. This suggests that 
different classes of human disease have different evolutionary histories, and the 
evolutionary histories influence the rates by which natural selection has been shaping 
these genes in species closer to humans. Therefore, different disease classes likely 
correspond to different sets of model organisms in which they can be accurately modeled. 
Importantly, my analysis shows that it may be possible to use evolutionary metrics to 
help inform what set of species are the most appropriate for a given class of disease 
genes. The findings I presented are consistent with a handful of recent reports in which 
traditional animal models have not been able to successfully reproduce the human 
phenotype in certain disease contexts. 
Next, using the newly sequenced genome of the ctenophore Mnemiopsis leidyi 
and small RNA sequencing data, I reported the first survey of the microRNA content in 
any ctenophore species. Surprisingly, I did not identify any canonical microRNAs or the 
key pathway components (Drosha and Pasha) that are responsible for miRNA biogenesis 
in animals. Prior to this work, the only other known case of an animal lacking miRNAs 
!!
124 
was the placozoan Trichoplax, whose miRNA absence is attributed to the loss of the 
Pasha protein. The implications of my work are two-fold: the results suggest that miRNA 
biogenesis may have evolved after the first animals, and that miRNAs were neither 
essential nor highly conserved during the earlier stages of animal evolution. Additional 
evidence reported since the culmination of this work reinforces these conclusions. 
Specifically, phylogenomic analysis revealed that Ctenophora is likely the sister group to 
the rest of animals (J. F. Ryan et al. 2013) and additional ctenophore species have been 
found to lack miRNAs (Moroz et al. 2014). Together, these findings support the scenario 
where ctenophores diverge from the rest of animals prior to the divergence of Porifera 
and prior to the emergence of miRNA functionality (Figure 2.5A). Additionally, a recent 
investigation into miRNA-based phylogenetic inference methods has demonstrated that 
such methodologies are unreliable (Thomson et al. 2014). This supports my conclusion 
that miRNAs were not highly conserved in the earliest animals and their use as 
phylogenetic markers is limited. In accordance with other surveys showing large-scale 
losses of microRNAs, these multiple lines of evidence contradict the theory that, due to 
the importance of microRNAs in fine-tuning gene expression, miRNAs are very rarely 
lost from the genome once they have evolved in an ancestral species. Rather, these data 
suggest that microRNAs were not essential in the earliest animals and, furthermore, may 
not have exhibited conservation on a large scale until later periods of animal evolution 
(e.g., within the bilateria). 
 Finally, the third chapter of this dissertation investigates microRNA regulatory 
functions within human clinical contexts. Specifically, this work presented a method 
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called SubmiRine for analyzing clinical genomic data sets in search of variants that alter 
microRNA target sites. SubmiRine utilizes TargetScan6 context+ scores as the 
underlying target site scoring mechanism, and I presented its application to a large patient 
cohort study on chronic obstructive pulmonary disease (COPD). I exhibited the power of 
SubmiRine to identify both known and novel microRNA target site variants (miR-TSVs) 
and also demonstrated its efficiency relative to open-source target site prediction tools. 
Together, these results reveal that SubmiRine is scalable to the size and complexity of 
large clinical genomic data sets and is also precise in its methodology for identifying and 
prioritizing variants with the highest probability of being functional and clinically 
relevant. This tool is the first of its kind and provides the clinical research community 
with a novel method to analyze microRNA regulatory functions dynamically and 
efficiently. 
 The advancements made in these studies open multiple opportunities for future 
work. The phylostratigraphic and selective rate analyses I have presented on human 
disease gene classes has provided a unique view on the evolution of the genetics 
underlying different human diseases. I hope that these insights lead to more efficient and 
effective research practices with animal models in a few particular ways. First, while the 
analysis I have performed does not present a researcher with a perfect match between a 
particular human disease gene and its best animal model, it does show that comparative 
genomics methods have the power to provide this level of detailed analysis. However, 
such a method will require more genome sequence data from additional animal species to 
enable detailed evolutionary profiling of classes of human disease genes, and no method 
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currently exists for predicting the suitability of a species for modeling a particular human 
gene. Second, we are already seeing major shifts in how animal models are utilized for 
genetic research, and ethical motivations are pushing for the use of “simpler” animal 
models when possible. In accordance with my findings that even non-bilaterian animals 
have surprisingly large inventories of human disease gene orthologs, it seems likely that 
expanding the set of animals with whole genome sequence available will yield intriguing 
new animal models to study aspects of human disease genetics in unprecedented ways. 
Lastly, this work conclusively demonstrated that not every human genetic disease has the 
same evolutionary origins. Thus, not every human disease should be studied in the same 
animal model. Increasing awareness of this fact will benefit the research community, 
particularly when these issues are worked out prior to investing time and resources into 
an inappropriate or suboptimal animal model. Furthermore, making the best effort to 
ensure that a choice in animal species will provide the best research outcomes promotes 
ethical usage of animals for research purposes. Together, I hope that these advancements 
to methods in modeling human disease genetics will lead to new insights into human 
disease and, ultimately, new therapeutics. 
The second chapter of this dissertation exemplifies the benefit of studying the 
genomes of animals that have previously been relatively unexplored. While ctenophores 
are unlikely to be the next blockbuster animal model for human disease genes, there are 
unequivocally biological insights relevant to humans that can be gained through the study 
of these distantly related animal species and sequencing their genomes. In this chapter, I 
showed that microRNAs may not have existed in the earliest animals, and ctenophores 
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may be the only animal species that function with a complete lack of the microRNA 
biogenesis pathway and its components. This could potentially be useful for revealing 
novel insights into the way the microRNA pathway emerged and how it functions on its 
most basic level. For example, given the absence of canonical microRNAs in the 
ctenophores, there is a possibility that an alternative mechanism exists by which these 
species, and possibly others, generate non-canonical microRNAs or similar regulatory 
small RNAs. While currently no such mechanism has been identified, it was recently 
reported that microRNAs regulate their targets differently in cnidarians than in bilaterian 
species (Moran et al. 2014), supporting the idea that the canonical microRNA regulatory 
pathway seen in humans is not identical in every animal species. Future research on the 
origins and evolution of the microRNA biogenesis pathway could potentially reveal 
alternative pathways that teach us more about microRNA regulatory functions in humans. 
  As evidenced by recent reports of frequent non-canonical binding by microRNAs 
to their targets in humans, it is clear that we do not fully understand the microRNA 
regulatory pathway and the rules by which microRNAs recognize their targets. Further 
confounding this problem is that we cannot easily verify (and quantify) binding in vivo. 
The third chapter of this dissertation utilizes the best of our current knowledge on 
microRNA regulation in the development of SubmiRine, but additional insights on the 
microRNA pathway could further improve our ability to predict human disease 
mechanisms related to microRNA functions. As technologies improve our ability to 
measure binding events, we may be able to better predict how and where microRNAs 
bind, as well as the conditions by which they effectively suppress translation of their 
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targets. It may be the case that microRNAs bind to their targets opportunistically and 
without regard for context, but that binding alone does not guarantee the target will be 
down-regulated. This may partially explain why recent studies have identified 
exceptionally high rates of non-canonical binding events, yet found that, generally, 
canonical target sites in the 3’UTR still appear to be the most repressive (Hafner et al. 
2010). Notwithstanding, there are likely conditions that govern microRNA regulatory 
functions that we do not currently understand. As our knowledge of this mechanism 
improves, it will also improve our ability to assess the effects of miR-TSVs. Furthermore, 
with the development of methods such as SubmiRine for assessing miR-TSVs, alongside 
the increasing number of studies producing clinical genomic data sets sufficient to assess 
allele-specific microRNA regulation, I anticipate that a growing number of functional 
miR-TSVs will be identified and verified experimentally. While such examples are 
relatively sparse at the current time, such additional examples may give us the ability to 
assess miR-TSVs in a novel way. For example, all current methodologies (including 
SubmiRine) rely on microRNA target site scoring methods; it may be possible to predict 
functional miR-TSVs independently of target site scoring methods that were designed for 
a different purpose once more robust data sets become available. 
 In conclusion, the work presented in this dissertation has made significant 
advancements to multiple fields of science through the use and development of methods 
in comparative and computational genomics. Most directly, this work has touched on 
areas of evolutionary biology, functional genomics, clinical genomics, and human disease 
genetics, and consequently, posed new, open questions of importance to these fields. I 
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hope that further investigation of these topics and additional developments in 
comparative genomics methodologies will yield clinically actionable information that 
directly or indirectly improves clinical practice and human health. !
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